Bio-Rad
Laboratories
2 02 2 ANNUAL REPORT
L E T T E R T O S T O C K H O L D E R S
This past year
marked the
70th anniversary
for Bio-Rad.
Founded with just several hundred dollars in
capital and a mission to advance scientific
discovery, a lot has transpired over the years.
From a handful of people, the Company has
grown to over 8,000 employees, thousands
of products, a global footprint, and leadership
positions in a number of exciting markets across
Life Science and Clinical Diagnostics. With
that, we have clear opportunities for continued
growth as we pursue our mission to advance
scientific discovery and improve healthcare.
2022 PRODUCT SPOTLIGHT
Immunohematology
LEADING THE WAY IN HIGH-QUALITY BLOOD TRANSFUSION PRODUCTS
In early 2023, Bio-Rad completed the
During 2022, in partnership with SANBS,
placement of our IH-500™ immunohematology
we successfully began installing Bio-Rad’s
systems across South Africa’s National Blood
IH-500 systems across the SANBS
Services (SANBS) network of transfusion
network of eighty-six labs and blood
medicine laboratories as part of an exclusive
banks throughout South Africa enabling
agreement finalized in early 2022.
high-quality and consistent lab testing
Launched in 2015 outside the US and in
2019 in the US, the IH-500 system is a
fully automated random-access platform
for blood typing and screening, providing
transfusion medicine labs with fast and
reliable results in a 24/7 environment.
across the provinces that rely on SANBS
to provide blood products and services to
South Africa’s citizens. This collaboration
and partnership has supported the South
African blood banks network’s need for
high-quality blood products and services
for the country’s citizens while enabling
Bio-Rad to gain a market leadership position
in the broader sub-Saharan African region.
20 22 P RODU CT SPOTLIGHT
Genesis Cell Isolation System
NEXT INNOVATION IN CIRCULATING TUMOR CELL DETECTION
During 2022, Bio-Rad continued to
genomics, digital PCR, or stained
extend its reach in oncology research
on-slide for immunofluorescent
applications with the introduction of
applications such as enumeration and
our Celselect Slides™, which offer an
identification of various CTCs and other
improved method for the enrichment
rare cell types. In the field of oncology,
and enumeration of circulating tumor
this type of sensitive detection of CTCs
cells (CTCs) in liquid biopsies.
from clinical samples and liquid biopsies
can serve as an effective tool in cancer
diagnosis and prognosis.
Celselect Slides™ are designed to
be used with Bio-Rad’s Genesis Cell
Isolation System to effectively capture
CTCs and other rare cells by size, in
under one hour. After capture, the
enriched cells can be recovered for
further analysis such as single-cell
L E T T E R T O S T O C K H O L D E R S ( C O N T I N U E D )
While our reported full-year 2022 sales of $2.8 billion
decreased by about 4% from the prior year, the
tough year-over-year comparison relates primarily to
a decrease in sales of pandemic-related products.
Subtracting out these COVID-related sales from both
years, and adjusting for non-operating items and
currency translations, our underlying growth was a
healthy 7.2%. Strong customer demand for our products
was impacted by the global supply chain challenges,
which compressed our 2022 operating income to about
19% from just over 20% in 2021.
Revenue from our underlying
business increased 7.2%* in 2022.
Early in the year, we were able to issue $1.2 billion
of bonds at very favorable rates, giving us additional
opportunities to invest in the business and to pursue
strategic acquisitions.
While the year was marked with geo-political
uncertainties, inflationary pressures, and supply chain
constraints, it was also a year of progress across many
* Currency-neutral, excluding COVID-related sales of approximately $109 million and $266 million,
respectively in 2022 and 2021, and a royalty-related legal settlement of $32 million in 2021.
B I O - R A D L A B O R ATO R I ES | 20 2 2 A N N UA L R E P O R T : 4
L E T T E R T O S T O C K H O L D E R S ( C O N T I N U E D )
fronts. We continued to advance many of our operational
transformation initiatives including relocating some of
our Europe-based manufacturing to Asia, consolidating
support operations in Budapest, launching a renewed
program around e-commerce, and improving the
alignment of operational functions to our strategic
objectives. All these efforts are instrumental to our goal
of measurable operational improvement.
We advanced our goal of
measurable operational
improvement.
It has also been a good year for new products, several of
which are featured in this report.
Among them is the QX-600, the latest in a series of
products utilizing droplet digital PCR technology. This
platform allows researchers to increase throughput and
complexity of their experiments. It also opens the door
to applications in diagnostics in areas including oncology
and women’s health. In the area of oncology, we also
introduced the Genesis Cell Isolation System, a platform
offering an improved method for enrichment and
enumeration of circulating tumor cells in liquid biopsies.
Expanding our tools for scientific research, we released
new Starbright Dyes and the Pioneer Antibody Screening
Library for use in drug discovery.
5 : B I O - R A D L A B O R ATO R I ES | 2 0 2 2 A N N UA L R E P O R T
2022 PRODUCT SPOTLIGHT
Droplet
Digital PCR
ADVANCING ONCOLOGY RESEARCH AND MOLECULAR DIAGNOSTICS
During 2022, Bio-Rad Introduced its QX600™
In November 2022, Bio-Rad further expanded
Droplet Digital™ PCR System to enable
its presence in oncology research through
new multiplexing applications in oncology
a licensing and product development
research, as well as gene expression, next-
agreement with genomics and molecular
generation sequencing (NGS) orthogonal
diagnostics company NuProbe™ USA. Under
testing, cell and gene therapy, and food and
the terms of the agreement, NuProbe USA
wastewater testing.
exclusively licensed its allele enrichment
technologies to Bio-Rad for the development
of multiplexed digital PCR assays. NuProbe’s
Blocker Displacement Amplification (BDA)
technology is a PCR method in which variant
DNA alleles are enriched over 1000-fold over
wild-type alleles. We expect this technology
to help advance Bio-Rad’s menu of products
in oncology, where highly sensitive and
multiplexed mutation detection assays aid
translational research, therapy selection, and
patient monitoring of minimal residual disease.
In addition, this platform supports our goal
of expanding into molecular diagnostics,
oncology, women’s health, and other clinical
application areas.
In oncology research, the QX600 system
allows researchers to collect more data per
well, thus helping to preserve often limited
circulating tumor DNA (ctDNA) and tumor
samples. The platform offers six-color
multiplexing and absolute quantification of
more than 12 targets per well with a simple
user workflow and best-in-class performance
that customers have come to expect from
Bio-Rad’s ddPCR™ systems.
202 2 PRODUCT SPOTLIG HT
PCR|ONE
IMPROVING SYNDROMIC INFECTIOUS DISEASE TESTING
In August 2022, Bio-Rad acquired
During 2023 and beyond, we plan
Curiosity Diagnostics™, a developer
to complete the development and
of innovative technology solutions
advance the commercialization
for the medical diagnostic and
of this “sample-to-result” rapid
healthcare markets. Curiosity’s
PCR|ONE system is a pre-
commercial platform technology
PCR technology for syndromic
infectious disease testing as part
of our molecular diagnostics
for the rapid, automated detection
strategy for clinical setting
of infections using highly
applications.
multiplexed PCR assays.
L E T T E R T O S T O C K H O L D E R S ( C O N T I N U E D )
In addition, during the second half of 2022 we acquired
a pre-commercial PCR platform. PCR I One, an
innovative, sample-to-answer, rapid PCR technology
intended to advance our molecular diagnostics strategy
in the area of syndromic infectious disease testing.
As we enter 2023, it is encouraging to see the many
ripple effects of the pandemic waning. This will allow
us to increase our focus on the many operational
improvements underway as we set the stage for
accelerated growth and improved operating margins.
We thank our customers, our valued employees
and stockholders for their ongoing commitment and
support as we continue our journey of transformation
and growth.
Norman Schwartz
PRESIDENT AND CEO
B I O - R A D L A B O R ATO R I ES | 20 2 2 A N N UA L R E P O R T : 8
The Year at a Glance
2022 FINANCIAL HIGHLIGHTS
FIVE-YEAR RECORD
(IN M IL LIO NS )
2018
2019
2020
2021
2022
Net Sales
Gross Profit
$ 2,289.4
$ 2,311.7
$ 2,545.6
$ 2,922.5
$ 2,802.2
$ 1,223.2
$ 1,257.0
$ 1,437.9
$ 1,638.1
$ 1,567.3
Operating Income (Loss)
Cash Flow from Operations
$
$
(103.3)
285.5
$
$
229.7
457.9
$
$
421.3
585.0
$
$
500.3
669.5
$
$
482.6
194.4
2022 SALES BY GROUP
(IN MILLIONS)
2022 SALES BY GROUP
(IN MI LL IO NS )
2022 SALES BY REGION
2022 SALES BY REGION
51.8%
Clinical
Diagnostics
48.1%
Life Science
47%
Americas
23%
Asia Pacific
30%
Europe
0.1%
Other
$ 2,289.4
$ 2,311.7
$ 2,545.6
$ 2,922.5
$ 2,802.2
NET SALES
(IN MILLIONS)
NET SALES
2018
(IN MI LL IO NS )
2019
2020
2021
2022
OPERATING INCOME (LOSS)
(IN MILLIONS)
CASH FLOW FROM OPERATIONS
(IN MILLIONS)
OPERATING INCOME (LOSS)
2018
(IN MILLIONS)
$ (103.3)
2019
2020
2021
2022
$ 229.7
$ 421.3
$ 500.3
$ 482.6
2018
2019
2020
2021
2022
$ 285.5
$ 457.9
$ 575.3
$ 656.5
$ 194.4
9 : B I O - R A D L A B O R ATO R I ES | 2 0 2 2 A N N UA L R E P O R T
$ 2,289.42018$ 2,311.72019$ 2,545.62020$ 2,922.52021NET SALES (IN MILLIONS)$ 2,802.22022$ (103.3)2018$ 229.72019$ 421.32020$ 500.32021OPERATING INCOME (LOSS)(IN MILLIONS)$ 482.62022$ 285.52018$ 457.92019$ 575.32020$ 656.52021CASH FLOW FROM OPERATIONS (IN MILLIONS)$ 194.420222022 SALES BY REGION47%Americas23%Asia Pacific30%Europe2022 SALES BY GROUP (IN MILLIONS)51.8%Clinical Diagnostics48.1%Life Science 0.1%Other$ 2,289.42018$ 2,311.72019$ 2,545.62020$ 2,922.52021NET SALES (IN MILLIONS)$ 2,802.22022$ (103.3)2018$ 229.72019$ 421.32020$ 500.32021OPERATING INCOME (LOSS)(IN MILLIONS)$ 482.62022$ 285.52018$ 457.92019$ 575.32020$ 656.52021CASH FLOW FROM OPERATIONS (IN MILLIONS)$ 194.420222022 SALES BY REGION47%Americas23%Asia Pacific30%Europe2022 SALES BY GROUP (IN MILLIONS)51.8%Clinical Diagnostics48.1%Life Science 0.1%Other
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the year ended December 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________________________ to _________________________________
Commission file number 1-7928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
94-1381833
(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,
Hercules,
(Address of principal executive offices)
California
94547
(Zip Code)
Registrant's telephone number, including area code
(510) 724-7000
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Class A Common Stock Par Value $0.0001 per share
Class B Common Stock Par Value $0.0001 per share
Securities registered pursuant to Section 12(g) of the Act: NONE
Trading
Symbols
BIO
BIOb
Name of Each Exchange on Which Registered
New York Stock Exchange
New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
☒ Yes
☐ No
☐ Yes
☒ No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes
¨ No
☒ Yes
¨ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer
Non-accelerated file
☒
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☐
☐
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public
accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
☒
☐
Yes ☒ No
As of June 30, 2022, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A
Common Stock held by non-affiliates was approximately $10,439,096,085 and the aggregate market value of the registrant's Class B Common Stock held by non-
affiliates was approximately $68,048,640.
As of February 14, 2023, there were 24,521,581 shares of Class A Common Stock and 5,074,130 shares of Class B Common Stock outstanding.
(1)
Definitive Proxy Statement to be mailed to stockholders in connection with the
registrant's 2023 Annual Meeting of Stockholders (specified portions)
Documents Incorporated by Reference
Document
Form 10-K Parts
III
BIO-RAD LABORATORIES, INC.
FORM 10-K DECEMBER 31, 2022
TABLE OF CONTENTS
Part I.
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
Part II.
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
Item 6. Reserved
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Part III.
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accountant Fees and Services
Part IV.
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10-K Summary
Signatures
3
3
11
24
24
25
25
25
25
26
26
41
42
95
95
96
96
96
96
97
97
97
97
98
98
101
101
2
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Other than statements of historical fact, statements made in this report include forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our future financial performance, operating results, plans and
objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such
as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the
negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual
results to vary materially from those expressed in or indicated by the forward-looking statements. We have based
these forward-looking statements on our current expectations and projections about future events. However, actual
results may differ materially from those currently anticipated depending on a variety of risk factors including, but
not limited to, the duration, severity and impact of the COVID-19 pandemic, supply chain issues, global economic
conditions, foreign currency exchange fluctuations, our ability to develop and market new or improved products,
our ability to compete effectively, reductions in government funding or capital spending of our customers,
international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired
companies, products or technologies into our company successfully, changes in the healthcare industry, natural
disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Item
1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking
statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events, or
otherwise, except as required by law.
PART I.
ITEM 1. BUSINESS
General
Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) is a multinational
manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Bio-Rad
manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad
range of products and systems used to separate complex chemical and biological materials and to identify, analyze
and purify their components.
We have direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus
is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales
efforts are supplemented by distributors and agents.
Description of Business
Business Segments
Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments
operate worldwide. Our Life Science segment and our Clinical Diagnostics segment generated 48% and 52%,
respectively, of our net sales for the year ended December 31, 2022. We generated approximately 41% of our
consolidated net sales for the year ended December 31, 2022 from the U.S. and approximately 59% from our
international locations, with Europe being our largest international region.
3
Life Science Segment
Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological
questions. These instruments, systems, reagents, and consumables are typically used to separate, purify,
characterize, or quantitate biological materials such as cells, proteins, and nucleic acids in the research laboratory or
the biopharmaceutical manufacturing and quality control process, for food safety and science education and literacy.
Many of our products are used in established research techniques, biopharmaceutical production processes and food
testing regimes. We are focused on the translational research market segment where our products help accelerate the
timelines from discovery in the lab to use in the clinic and with patients. We are a leader in the life sciences market
and develop, manufacture and market a broad portfolio of many thousands of products that serve a global customer
base. We focus on specific segments of the life sciences market in proteomics (the study of proteins), genomics (the
study of genes), biopharmaceutical production, cellular biology and food safety. We estimate that the worldwide
market that our portfolios can address for products in these selected segments of our addressable markets is
approximately $19 billion. Our principal life science customers include universities and medical schools, industrial
research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food
producers and food testing laboratories.
Clinical Diagnostics Segment
Our Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems,
test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Our
products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on
the higher margin, higher growth segments of this market.
We supply several thousand products that cover more than 300 clinical diagnostic tests to the IVD test market. We
estimate that the worldwide sales for products in the markets we serve is approximately $16 billion. IVD tests are
conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or
urine. Our products consist of reagents, instruments and software, typically provided to our customers as an
integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring,
as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment,
reagent and consumable products. An installed base of diagnostic test systems therefore typically creates a recurring
source of revenue through the sale of test kits for each sample analyzed on an installed system. Our principal
clinical diagnostic customers include hospital laboratories, diagnostic reference laboratories, transfusion laboratories
and physician office laboratories.
Raw Materials and Components
We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical
parts, computing and peripheral devices. Most of these materials and components are available from numerous
sources, and while we have historically not experienced difficulty in securing adequate supplies, the impact of
COVID-19 on our suppliers' operations has created on-going challenges in procuring materials. For more discussion
relating to the impacts of the COVID-19 pandemic and the difficulty of securing adequate supplies, please see “Item
1A, Risk Factors” to this Annual Report. In certain instances, we acquire components and materials from a sole
supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional
or replacement sources for some components or materials.
Patents, Trademarks and Licenses
We own over 2,300 U.S. and international patents and numerous trademarks. We also hold licenses under U.S. and
foreign patents owned by third parties and pay royalties on the sales of certain products under these licenses. In
addition, we also receive royalties for licenses of our intellectual property. We view these patents, trademarks and
license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products
depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing
positions.
4
Seasonal Operations
Our business is not inherently seasonal. However, the European custom of concentrating vacation during the
summer months usually tempers third quarter sales volume and operating income.
Sales and Marketing
We conduct our worldwide operations through an extensive direct sales force, employing approximately 830 direct
sales and sales management personnel around the world. Our sales force typically consists of experienced industry
professionals with scientific training, and we maintain a separate specialized sales force for each of our segments.
We believe that this direct sales approach allows us to sell a broader range of our products that creates more brand
awareness and long-term relationships with our customers.
We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs
we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs to
ensure their compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a
transparent sale to our customers.
Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and
research institutions; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic
manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries.
Our sales are affected by a number of external factors. For example, a number of our customers, particularly in the
Life Science segment, are substantially dependent on government grants and research contracts for their funding.
Most of our international sales are generated by our wholly-owned international subsidiaries and their branch
offices. Certain of these subsidiaries also have manufacturing operations. Bio-Rad’s international operations are
subject to certain risks common to foreign operations in general, such as changes in governmental regulations,
import restrictions and foreign exchange fluctuations.
Competition
The markets served by our product groups are highly competitive. Our competitors range in size from start-ups to
large multinational corporations with significant resources and reach. We seek to compete primarily in market
segments where the technology and efficacy of our products offer customers specific advantages over the
competition.
Our Life Science segment does not face the same competitors for all of its products due to the breadth of its product
lines. Major competitors in this market include Becton Dickinson, GE Biosciences, Merck Millipore and Thermo
Fisher Scientific. We compete primarily based on meeting performance specifications and offering comprehensive
solutions.
Major competitors for our products in the Clinical Diagnostics segment include Roche, Abbott Laboratories,
Siemens, Danaher, Thermo Fisher Scientific, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh,
Immucor and DiaSorin. We compete across a variety of attributes including quality, service and product portfolio.
5
Research and Development
We conduct extensive research and development activities in all areas of our business. Research and development
has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams
are continuously developing new products and new applications for existing products. In our development of new
products and applications, we interact with scientific and medical professionals at pharma and bio-pharma
companies, universities, hospitals and medical schools, and within our industry. In addition, we regularly invest in
companies that are engaged in the development of new technologies that either complement or expand our existing
portfolio of products. We have approximately 1,110 employees worldwide focused on research and development,
including degreed scientists, engineers, software developers and other technical support staff.
Regulatory Matters
The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling
of certain of our products (primarily diagnostic and donor screening products) are subject to regulation in the United
States by the Center for Devices and Radiological Health (CDRH) and/or the Center for Biologics Evaluation and
Research (CBER) of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign
government authorities. FDA regulations require that some new products have pre-marketing notification (“510(k)”)
or approval (“PMA” or Biologics License Application – “BLA”) by the FDA and require certain products to be
manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to
be properly labeled to disclose test results and performance claims and limitations. The FDA’s 510(k) clearance
process requires regulatory competence to execute and usually takes four to nine months, but it can take longer. The
FDA’s PMA and BLA processes require extensive regulatory competence to execute and may take one to two years.
A clinical trial is generally required to support a PMA or BLA application and is sometimes required for a 510(k)
clearance or a de novo authorization. Conducting clinical trials is a complex and costly activity and frequently
requires the use of outsourced resources that specialize in planning and conducting the clinical trial for the medical
device manufacturer.
The European Union (“EU”) has adopted the EU in-vitro Diagnostics Regulation (the “EU IVDR”), which imposes
stricter requirements for the marketing and sale of in-vitro diagnostics products (as compared to the predecessor in-
vitro Diagnostics Directive (IVDD)), including in the areas of clinical evaluation requirements, quality systems,
economic operators and post-market surveillance. Manufacturers of currently marketed in-vitro diagnostics products
had until May 2022 to meet the requirements of the EU IVDR, though the EU Council and Parliament signed an
amendment that delays certain previously mandated deadlines to allow more time for Notified Body of EU countries
to manage the entire portfolio of IVD products on the European market. Bio-Rad's IVD products currently meet the
requirements of the EU IVDR.
Our manufacturing facilities, as well as those of certain suppliers, are subject to periodic inspections by the FDA
and other regulatory bodies to verify compliance with regulatory requirements. Similar inspections are performed
by Notified Bodies to verify compliance to applicable ISO standards (e.g. ISO 13485:2016), requirements under the
Medical Device Single Audit Program ("MDSAP") applicable to regulatory requirements of Australia, Brazil,
Canada, Japan and the U.S. and/or medical device regulations and requirements from the countries in which we
distribute product and other specified audits by regulatory authorities. If a regulatory body were to find that we or
certain suppliers have failed to comply with applicable regulations (e.g. recordkeeping, reporting of adverse events),
it could institute a wide variety of enforcement actions, ranging from issuance of a warning or untitled letter to more
severe sanctions, such as product recalls or seizures, civil penalties, consent decrees, injunctions, criminal
prosecution, operating restrictions, partial suspension or shutdown of production, refusal to permit importation or
exportation, refusal to grant, or delays in granting, clearances or approvals or withdrawal or suspension of existing
clearances or approvals. Any of these actions could have an adverse effect on our business.
6
We are also subject to additional regulation and enforcement by the federal government and by authorities in the
states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and
federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and
regulations. If our operations are found to be in violation of any such laws or any other governmental regulations
that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages,
fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare
programs and imprisonment.
Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products
will be covered by third-party payors, such as government health care programs, commercial insurance and
managed healthcare organizations. These third-party payors are increasingly adjusting reimbursements for certain
medical products and services. In addition, the U.S. government, state legislatures and foreign governments have
continued implementing cost containment programs, including price controls and restrictions on reimbursement.
Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit our net revenue and results. Decreases in third-party
reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not
cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our
sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be
adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and
services, which could result in reduced demand for our products or additional pricing pressures.
As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of
electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the
European Union and other jurisdictions.
Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern
activities such as transportation of goods, emissions to air and discharges to water, as well as handling and disposal
practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we
are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills,
disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise
impacting real property that we own or operate. The environmental laws and regulations could also subject us to
claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or
at any of our properties.
These regulatory requirements vary widely among countries.
Human Capital Resources
At Bio-Rad, we consider our employees to be our most valuable asset, and critical to the effective development,
manufacture, sale, distribution and servicing of our vast array of products and services. Our employees are essential
to satisfying our customers’ needs for products to advance science and healthcare. At December 31, 2022, we had
approximately 8,200 employees, the overwhelming majority of which are full-time employees. Our employees are
located throughout the world with roughly 46% in the Americas, 37% in Europe, the Middle-East and Africa, and
17% in Asia Pacific. Our employees work in over 140 locations in 36 different countries around the world.
7
Diversity, Equity and Inclusion
At Bio-Rad, we recognize that diversity is a strength. Our differences offer new and unique ideas and perspectives
to our organization. We foster a work culture that embraces the diverse experience and knowledge of every
employee, creating an inclusive culture regardless of race, gender, age, sexual orientation, disability, or nationality.
We have been purposeful in our efforts to hire, develop and retain diverse talent as well as in our efforts to create an
inclusive culture. We actively encourage employee engagement and regularly solicit feedback regarding job
satisfaction, career growth and development, collaboration, empowerment, ethics, and manager effectiveness. We
use employee input to help our managers make focused and strategic commitments to improve and sustain
engagement in their teams. Bio-Rad requires that all management and employees participate in ongoing training
intended to increase awareness of the importance of a diverse and inclusive culture.
Compensation and Benefits
We provide a competitive total rewards program consisting of broad-based salary and bonus plans as well as annual
stock grants to management level employees. These programs combine to recognize and reward employees based
on individual, group, and overall company performance. We provide competitive health and welfare programs
which include medical, dental, vision and life insurance, a 401(k) plan, an employee stock purchase program, local
pension plans, profit sharing, employee assistance, child and elder care programs, employee recognition and a host
of other localized programs tied to the unique needs of our employees. Pay equity is an integral part of our
compensation strategy. We have established ongoing processes and protocols to help us pay each individual
employee appropriately based on the employee's skills, performance, experience, location, market practices, etc.,
regardless of race, gender and other non-performance related attributes.
Health, Wellness and Safety
The health and welfare of our employees is of the highest importance to Bio-Rad. We prioritize, manage, and
carefully track safety performance at all locations globally and integrate sound safety practices in every aspect of
our operations. We provide work site hazard evaluations, workplace safety surveys, safety equipment selection,
safety program reviews, chemical exposure monitoring, safety training, and disposal of hazardous chemical and
infectious waste. In March 2020, we began to implement certain changes in an effort to protect our employees and
customers from COVID-related exposures. For example, we implemented social distancing in the workplace,
extensive cleaning and sanitation processes for both production and office spaces, and broad work-from-home
initiatives for employees in our administrative functions. In 2021, we instituted a COVID-19 vaccine requirement
in the United States to help contribute to a safer workplace. We also continue to require employees to isolate and
quarantine when appropriate to protect their fellow workers and deploy rapid COVID-19 testing when appropriate.
Throughout the pandemic, essential workers continued to work at our facilities and provide vital service to our
customers. Beginning in early 2022 most of the employees in our administrative functions began returning to the
office several days each week and we anticipate they will be spending more time on site as pandemic conditions
continue to improve. Starting in 2023, we introduced an upgraded and streamlined mental health/Employee
Assistance Program solution tailored to the need and preference of employees and families. In addition, we added a
fertility benefit giving employees access to a suite of services including pregnancy resources, in vitro fertilization
(“IVF”), adoption, donor and surrogate services resources.
Training and Talent Development
We provide training programs for managers and employees to support their growth and development. Our
management series of courses cover essential management and leadership learning to provide our managers with the
necessary skills and experience needed to more effectively lead and develop their teams. In addition, available
courses for employees help them to be more effective at work, enhance interpersonal effectiveness, and help them
achieve their full potential. We also support employees’ professional development by providing a reimbursement
program for qualified educational expenses.
8
Investment in Sartorius AG
Sartorius AG ("Sartorius") is an international laboratory and process technology provider for the biotech,
pharmaceutical, and food industries. It operates in two divisions – Bioprocess Solutions Division and Lab Products
& Services Division. Sartorius is headquartered in Gottingen, Niedersachsen, Germany and has voting ordinary
shares as well as non-voting preference shares listed on XETRA and the Frankfurt Stock Exchanges.
As of December 31, 2022, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius,
representing approximately 37% of the outstanding ordinary shares (excluding treasury shares) and 28% of the
preference shares of Sartorius. As of December 31, 2022, the fair value of the investment in Sartorius was $8,473.8
million.
The following summarizes certain financial data of Sartorius as of and for the year ended December 31, 2021, (in
thousands).
Current assets
Non-current assets
Current liabilities
Non-current liabilities
Equity
Sales revenue
Gross profit on sales
Earnings before interest and taxes (EBIT)
Net profit
Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities
€
December 31, 2021 (1)
1,796,802
3,901,130
1,547,164
2,430,572
1,720,196
Year Ended December 31, 2021 (1)
3,449,222
€
1,838,926
903,155
426,978
865,814
(569,607)
(165,182)
(1) As disclosed in Sartorius AG's consolidated financial statements for the year ended December 31, 2021,
prepared in accordance with the International Financial Reporting Standards (IFRS), the International
Financial Reporting Interpretations Committee (IFRIC) Standards, and the International Accounting
Standards Board (IASB) as required to be applied by the European Union, and based upon information
publicly disclosed by Sartorius. Bio-Rad does not assume, and by way of referencing the financial data of
Sartorius above shall not be deemed to assume, any responsibility or liability for any errors or omissions in
the information publicly disclosed by Sartorius.
Refer to Sartorius’ 2021 Annual Report for further details, which can be found at https://www.sartorius.com/en/
company/investor-relations/sartorius-ag-investor-relations. The Sartorius website and any information disclosed
thereon are not incorporated by reference into this report.
The following graph reflects the changes in the Sartorius share price over the most recent five annual periods:
9
Sartorius Stock Price
S
O
R
U
E
700
600
500
400
300
200
100
—
2017
2018
2019
2020
2021
2022
Preference per share price (EUR)
Ordinary per share price (EUR)
Available Information
Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and
Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended. The SEC maintains an
Internet website that contains reports, proxy and information statements, and other information regarding issuers,
including Bio-Rad, that file electronically with the SEC. The public can obtain any documents that we file with the
SEC at http://www.sec.gov.
Bio-Rad’s website address is www.bio-rad.com. We make available, free of charge through our website, our Form
10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the
SEC. The information on our website is not part of this Annual Report on Form 10-K.
10
ITEM 1A. RISK FACTORS
In evaluating our business and whether to invest in any of our securities, you should carefully read the following
risk factors in addition to the other information contained in this report. We believe that any of the following risks
could have a material effect on our business, results of operations or financial condition, our industry or the trading
price of our common stock. We operate in a continually changing business environment, and new risks and
uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the
extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth
below may adversely affect our business, results of operations, financial condition, our industry, the value of our
equity holdings, or the trading price of our common stock. Please carefully consider the following discussion of
significant factors, events and uncertainties that make an investment in our securities risky and provide important
information for the understanding of the “forward-looking” statements discussed this report. In addition to the
effects of the COVID-19 pandemic and resulting global disruptions on our business and operations discussed in this
report, additional or unforeseen effects from the COVID-19 pandemic and the global economic climate may give
rise to or amplify many of these risks discussed below.
Business, Economic, Legal and Industry Risks
Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely
affect our business, operations, financial condition, and results of operations.
Although we expect conditions relating to COVID-19 will continue to improve, the COVID-19 pandemic has had
and if conditions deteriorate again, could continue to have an adverse effect on the United States and global
economies, as well as on aspects of our business, operations, and financial condition and those of third parties on
whom we rely.
Although we experienced increased demand for certain of our products used in fighting the COVID-19 pandemic,
we previously experienced some decreases in product demand in certain of our other businesses. If conditions
related to the pandemic were to deteriorate, we expect that parts of our business could again suffer negative impacts
from the pandemic. For example, lockdowns in China in 2022 had a negative impact on our business in China for
the second, third, and fourth quarters of 2022, and we expect that if any similar lockdowns and restrictions in China
are implemented in the future our business in China could be negatively impacted. The spread of COVID-19 in
China resulting from the lifting of lockdowns could also negatively impact our business in China.
On the supply side, we are experiencing continued but moderating challenges with the supply of raw materials and
components used in the production of our products. There are currently industry wide supply shortages of certain
raw materials and electronic components. These shortages have caused a backlog of sales orders, some of which we
consider to be significant, and some delays in certain new product development activities. Some of the backlog of
sales orders will continue into 2023. We have experienced raw material cost increases as a result of the COVID-19
pandemic, which will likely continue. In addition, while logistics capacity constraints are improving, we continue to
experience freight surcharges and expect these to continue at least for the near term. Some countries continue to
impose measures that may restrict the movement of our goods.
With respect to our personnel, although we adhere to government mandated and Environmental, Health and Safety
protocols, an outbreak of COVID-19 at one or more of our facilities could cause shutdowns of facilities and a
reduction in our workforce, which could dramatically affect our ability to operate our business and our financial
results.
The duration of the COVID-19 pandemic is unknown, and it is difficult to predict the full extent of potential impacts
the pandemic could have in the future on our business, operations, and financial results, or on our customers,
suppliers, logistics providers, or on the global economy.
11
A reduction or interruption in the supply of components and raw materials has adversely affected and could
continue to adversely affect our manufacturing operations and related product sales.
The manufacture of our products requires the timely delivery of sufficient amounts of quality components and
materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our
components and materials from many suppliers in various countries. We work closely with our suppliers to ensure
the continuity of supply, but we cannot guarantee these efforts will always be successful. Further, while we seek to
diversify our sources of components and materials, in certain instances we acquire components and materials from a
sole supplier. The COVID-19 pandemic has created delays and shortages in the supply of components and raw
materials. These shortages have caused a backlog of sales orders, some of which we consider to be significant, and
some delays in certain new product development activities. Some of the backlog of sales orders will continue into
2023. We have experienced raw material cost increases as a result of the COVID-19 pandemic, which will likely
continue. In addition, due to the regulatory environment in which we operate, we may need to cease use of certain
essential components and materials and be unable to quickly establish acceptable replacement sources for such
components or materials. When our supply is reduced or interrupted or of poor quality, and we are unable to
develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective
manner is adversely affected, which adversely affects our ability to sell our products. See also our risk factor
regarding the COVID-19 pandemic above.
Our international operations expose us to additional costs and legal and regulatory risks, which could have a
material adverse effect on our business, results of operations and financial condition.
We have significant international operations. We have direct distribution channels in over 35 countries outside the
United States, and during the twelve months ended December 31, 2022 our foreign entities generated 59% of our
net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations
increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include,
among others, data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import and
trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign
Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign
Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments
to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or
regulations potentially could be disruptive to our operations and business relationships in the affected regions.
Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international
operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or
negligent behavior of individual employees, our failure to comply with certain formal documentation requirements,
or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges
through policies, procedures and internal controls. However, we have a dispersed international sales organization,
and we use distributors and agents in many of our international operations. This structure makes it more difficult for
us to ensure that our international selling operations comply with laws and regulations, and our global policies and
procedures.
Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our
employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and
regulations also could result in prohibitions on our ability to offer our products in one or more countries and could
materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain
employees, or our business, results of operations and financial condition. See also our risk factors regarding the
COVID-19 pandemic above and regarding government regulations and global economic conditions below.
12
The industries and market segments in which we operate are highly competitive, and we may not be able to
compete effectively.
The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater
financial resources than we do, making them better equipped to license technologies and intellectual property from
third parties or to fund research and development, manufacturing and marketing efforts, or to source high-demand
materials and components. Moreover, competitive and regulatory conditions in many markets in which we operate
restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting
from inflation and other drivers of cost increases. Many public tenders have become more competitive due to
governments lengthening the commitments of their public tenders to multiple years, which reduce the number of
tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our
competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing
pressures resulting from competition could adversely affect our business, results of operations and financial
condition.
We may not be able to grow our business because of our failure to develop new or improved products.
Our future growth depends in part on our ability to continue to improve our product offerings and develop and
introduce new product lines and extensions that integrate technological advances. If we are unable to integrate
technological advances into our product offerings or to design, develop, manufacture and market new product lines
and extensions successfully and in a timely manner, our business, results of operations and financial condition will
be adversely affected. The COVID-19 pandemic and supply chain disruptions have caused some delays to our
ability to develop and introduce new products. We have experienced product launch delays in the past and may do
so in the future. We cannot assure you that our product and process development efforts will be successful or that
new products we introduce will achieve market acceptance. Failure to launch successful new products or
improvements to existing products may cause our products to become obsolete, which could harm our business,
results of operations and financial condition.
Breaches of our information systems could have a material adverse effect on our business and results of
operations.
We have experienced and expect to continue to experience attempts by computer programmers and hackers to attack
and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in
Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels,
we collect and store confidential information that customers provide to, among other things, purchase products or
services, enroll in promotional programs and register on our web site. We also acquire and retain information about
suppliers and employees in the normal course of business. Such information on our systems includes personally
identifiable information and, in limited instances, protected health information. We also create and maintain
proprietary information that is critical to our business, such as our product designs and manufacturing processes.
Despite recent initiatives to improve our technology systems, such as our enterprise resource planning
implementation and the centralization of our global information technology organization, we could experience a
significant data security breach. The Company is also subject to phishing and other fraud schemes including
fraudulent vendor communications with requests for payments and fraudulent attempts to redirect payments to
improper bank accounts, some of which have been successful. While the Company has adopted training and process
changes to limit the success of such fraudulent activity, the Company will be unable to stop all such fraudulent
activity which may lead to unrecoverable payments to criminal accounts. Increased use of remote work
arrangements and rapidly evolving work scenarios in response to the COVID-19 pandemic expose us to additional
risk of cyberattack and disruption. Because the techniques used to obtain unauthorized access, disable or degrade
service, or sabotage systems change frequently and often are not recognized until launched against a target, we may
not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers
have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information
systems and, if successful, could misappropriate confidential customer, supplier, employee or other business
information, such as our intellectual property. Third parties could also gain control of our systems and use them for
criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting
13
new customers, be exposed to claims from customers and suppliers, financial institutions, payment card
associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional
expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations
and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they
were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or
destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and
results of operations. See also our risk factors regarding our information technology systems and our enterprise
resource planning system (ERP) implementation below.
If our information technology systems are disrupted, or if we fail to successfully implement, manage and
integrate our information technology and reporting systems, our business, results of operations and financial
condition could be harmed.
Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT
systems (which increasingly include cloud-based systems provided by third party vendors) could have a material
adverse effect on our business, results of operations and financial condition. We depend on our IT systems to
process orders, manage inventory and collect accounts receivable. Our IT systems also allow us to efficiently
purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective
operations and provide customer service. We may experience disruption of our IT systems due to redundancy issues
with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current
level of efficiency.
Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and
analytical processes. We expect that we will need to continue to improve and further integrate our IT systems,
reporting systems and operating procedures by training and educating our employees with respect to these
improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer
interruptions in service, loss of data or reduced functionality when we upgrade or change systems or migrate to
cloud-based systems. If we fail to successfully manage and integrate our IT systems, reporting systems and
operating procedures, it could adversely affect our business, results of operations and financial condition. See also
our risk factors regarding our data security above and ERP implementation and events beyond our control below.
We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our
results of operations and financial condition.
As stated above, a significant portion of our operations and sales are outside of the United States. When we make
purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies
relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our
international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar
negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens,
our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact
our operations outside of the United States and increase our costs to hedge against currency fluctuations. In
addition, we hold investments and a loan receivable that are subject to foreign exchange fluctuations. We cannot
assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of
operations and financial condition.
Changes in the market value of our position in Sartorius AG materially impact our financial results.
Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated
statements of income and other financial statements. A decline in the market value of our position in Sartorius AG
will result in losses due to write-downs in the value of the equity securities. An increase in the market value of our
position in Sartorius AG will result in a favorable impact to net income independent of the actual operating
performance of our business. Depending on the extent of the decline or of the increase in the market value of our
position in Sartorius AG, these negative or positive impacts on us could be significant and material.
14
Our share price may change significantly based upon changes in the market value of our position in Sartorius AG,
and such change is independent of the actual performance of our business. Additionally, non-operating income for
a period may be significantly impacted by any distribution of dividends by Sartorius AG, particularly when the
dividends amount varies in comparison to prior year periods.
The value of our position in Sartorius AG might cause us to be deemed an investment company under the
Investment Company Act of 1940.
As a result of the market value of our position in Sartorius AG, we might be deemed to be an “investment company”
under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the “Investment Company Act”).
The Company does not believe it is an investment company primarily in reliance on Section 3(b)(1) of the
Investment Company Act because we are “primarily engaged” in a business other than that of investing, reinvesting,
owning, holding or trading in securities. Rather, we are primarily engaged in the development, manufacturing and
marketing of products for the life science research and clinical diagnostic markets, and we believe that our historical
development, our public representations of policy, the activity of our officers and directors, the nature of our present
assets, the sources of our present income, and the public perception of the nature of our business all support the
conclusion that we are an operating company and not an investment company. Although we have discussed this
issue with the staff of the SEC and we are comfortable with our position, if it is determined later that the Company
may not rely on Section 3(b)(1) or any other exemption under the Investment Company Act, and the Company were
deemed to be an unregistered investment company, such determination would have a material adverse effect on our
business as we would need to register as an investment company and be subject to the regulations of the Investment
Company Act which are designed to restrict and regulate mutual funds rather than operating companies. It could
also call into question the validity of all contracts to which the Company is a party. If it appeared likely that we
would be deemed to be an investment company, we may modify our position in Sartorius AG in order to avoid such
determination.
We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar
instruments. Financial markets are volatile and the markets for these securities can be illiquid. The value of these
securities will continue to be impacted by external market factors including default rates, changes in the value of the
underlying property, such as residential or commercial real estate, rating agency actions, the prices at which
observable market transactions occur and the financial strength of various entities, such as financial guarantors who
provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell
these instruments without significant losses due to current debtor financial conditions, low trading volume of the
securities, or other market considerations.
As discussed further in the Notes to Consolidated Financial Statements, in Note 3. Fair Value Measurements and
Investments, under the heading “Level 3 Fair Value Investments”, we made a loan of 400 million Euros to Sartorius-
Herbst Beteiligungen II GmbH in November 2021 that is secured by the pledge of certain trust interests which upon
termination of the trust represent the right to receive Sartorius ordinary shares (the "Loan"). Prior to a termination of
the trust, the trust interests, which are provided as collateral for the Loan, are not tradable on the capital markets and
may, in case of an enforcement, have to be sold with a significant discount to the value of the underlying shares.
We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile
and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments
in equity securities could result in significant losses due to write-downs in the value of the equity securities. Also, if
we need to convert these positions to cash, we may not be able to sell these equity securities without significant
losses. In addition, a significant decline in the value of the Sartorius ordinary shares would reduce the value of the
collateral for the Loan discussed in the previous paragraph, and in such circumstances the value of the collateral
may be insufficient to cover the repayment of the Loan, and Sartorius-Herbst Beteiligungen II GmbH will likely
have no other assets from which to repay the Loan. Furthermore, the change in the market value of Sartorius
ordinary shares will have an impact on the value appreciation rights acquired in connection with the Loan discussed
in the previous paragraph.
15
We may experience difficulties implementing our new global enterprise resource planning system.
We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The
ERP is designed to efficiently maintain our books and records and provide information important to the operation of
our business to our management team. The ERP will continue to require significant investment of human and
financial resources. In implementing the ERP, we may experience significant delays, increased costs and other
difficulties, as we already have with some of our earlier deployments. Any significant disruption or deficiency in the
design and implementation of the ERP could adversely affect our ability to process orders, ship product, send
invoices and track payments, fulfill contractual obligations or otherwise operate our business. We expect to
implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to
centralize various business processes and functions within our organization in connection with our ERP
implementation may continue to disrupt our operations and negatively impact our business, results of operations and
financial condition.
Recent and planned changes to our organizational structure could negatively impact our business.
We made significant changes to our organizational structure over the past few years, including the reorganization of
aspects of our European operations that was announced in February 2021. These changes may have unintended
consequences, such as distraction of our management and employees, labor unrest, business disruption, disruption
of supply, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or
productivity.
Risks relating to intellectual property rights may negatively impact our business.
We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure
agreements to protect our intellectual property rights and products. However, we cannot assure you that our
intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that
meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have
attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as
proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally,
third parties have asserted patent, copyright and other intellectual property rights to technologies that are important
to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our
products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and
marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or
defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur
substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed
party. Any of the foregoing matters could adversely impact our business, results of operations and financial
condition.
Global economic and geopolitical conditions could adversely affect our operations.
In recent years, we have been faced with very challenging global economic conditions. The COVID-19 pandemic,
as discussed above, has caused disruptions to global economic conditions. Russia’s invasion of Ukraine and
sanctions against Russia also are causing disruptions to global economic conditions and are negatively impacting
our business in Russia. It is unknown how long such disruptions will continue and whether such disruptions will
become more severe. A deterioration in the global economic environment may result in a decrease in demand for
our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A
weakening of macroeconomic conditions is also adversely affecting our suppliers, which could continue to result in
interruptions in the supply of the components and raw materials necessary for our products and raw material cost
increases. Additionally, the United States and other countries, such as China and India, recently have imposed
tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant
impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability
and/or our competitiveness. See also our risk factors regarding the COVID-19 pandemic and our international
operations above and regarding government regulations below.
16
Reductions in government funding and the capital spending programs of our customers could have a material
adverse effect on our business, results of operations or financial condition.
Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and
pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and
companies have a significant effect on the demand for our products. Such programs are based on a wide variety of
factors, including the resources available to make such purchases, the availability of funding from grants by
governments or government agencies, the spending priorities for various types of equipment and the policies
regarding capital expenditures during industry downturns or recessionary periods. If government funding to our
customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to
us, our business, results of operations or financial condition could be materially and adversely affected.
Changes in the healthcare industry could have an adverse effect on our business, results of operations and
financial condition.
There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs.
These changes include:
•
•
The trend towards managed care, together with healthcare reform of the delivery system in the United
States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other
participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers
and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful
groups, whose purchasing power gives them cost containment leverage. In particular, there has been a
consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and
competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse
effect on our gross margins for products we sell in clinical diagnostic markets.
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements
for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of
reimbursement available for clinical tests from third party payors. In the United States payment for many
diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical
Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers
for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in
establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform
certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third
party payors will offer adequate reimbursement for tests utilizing our products to make them commercially
attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of
2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the
Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will
pay for clinical laboratory services, which has further reduced reimbursement rates.
To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures
such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical
tests being performed or the amount of reimbursement available for such tests, our business, results of operations
and financial condition could be adversely affected. If these changes in the healthcare markets in the United States
and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our
products.
17
We are subject to substantial government regulation, and any changes in regulation or violations of regulations
by us could adversely affect our business, prospects, results of operations or financial condition.
Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject
to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign
counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to
significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements
including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting
regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety
of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to
suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of
production, withdrawal of approvals or clearances already granted, and criminal prosecution.
The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In
addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing
regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our
ability to modify our currently approved or cleared products on a timely basis. Any delay in, or failure to receive or
maintain, clearance or approval for our products or changes in regulation could prevent us from generating revenue
from these products and adversely affect our business operations and financial results. Additionally, the FDA and
other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased
scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using
our products.
Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale
and use of our products. Such agencies may also impose new requirements that may require us to modify or re-
register products already on the market or otherwise impact our ability to market our products in those countries.
For example, the EU in-vitro Diagnostics Regulation (the “EU IVDR”) includes broad changes regarding in vitro
diagnostic devices and medical devices. The implementation date for the EU IVDR was May 2022, though the EU
Council and Parliament signed an amendment that delays certain previously mandated deadlines to allow more time
for Notified Body to manage the entire portfolio of IVD products on the European market. The EU IVDR requires
us to modify or re-register some products and will result in additional costs Failure to meet these requirements
could adversely impact our business in the EU and other regions that tie their product registrations to the EU
requirements. In addition, Russia has enacted more stringent medical product registration and labeling regulations,
China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose
more regulations that impact our product registrations. The United Kingdom's withdrawal from the European Union
is resulting in additional regulatory requirements associated with goods manufactured and sold in the United
Kingdom and additional complexities and delays with respect to goods, raw materials and personnel moving
between the United Kingdom and the European Union. In addition, new government administrations may interpret
existing regulations or practices differently. Due to these evolving and diverse requirements, we face uncertain
product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or
fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local
companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing
measures to restrict access to such tenders for companies without local manufacturing capabilities. Certain tenders
in China and India also are including local manufacturing preferences or requirements. Such regulations could
adversely affect our business, results of operations and financial condition. See also our risk factors regarding our
international operations and regarding global economic and geopolitical conditions above.
We are also subject to government regulation of the use and handling of a number of materials and controlled
substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting,
storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of
1970. Failure to comply with present or future laws and regulations could result in substantial liability to us,
suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us
to make significant capital expenditures or incur other significant expenses.
18
We cannot assure you that we will be able to integrate acquired companies, products or technologies into our
company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.
As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies,
products and technologies. The benefits of any acquisition or investment may prove to be less than anticipated and
may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could
cause significant diversion of our management’s time and resources. If we acquire or invest in new companies,
products or technologies, we may be required to assume contingent liabilities or record impairment charges for
goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to
impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain
intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to
changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast
in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external
factors change detrimentally, future impairment losses may occur, as they have occurred in the past. Increased
antitrust enforcement and greater government scrutiny of mergers in the healthcare sector may impact our
ability to consummate acquisitions. We cannot assure you that we will successfully overcome these risks or any
other problems we encounter in connection with any acquisitions or investments, and any such acquisitions or
investments could adversely affect our business, results of operations and financial condition.
Product quality and liability issues could harm our reputation and negatively impact our business, results of
operations and financial condition.
We must adequately address quality issues associated with our products, including defects in our engineering,
design and manufacturing processes, as well as defects in third-party components included in our products. Our
instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially
those affecting reagents or third-party components, is difficult. We may incur significant costs and expend
substantial time in researching and remediating such issues. Quality issues could also delay our launching or
manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate
disclosure of risks related to our products, could result in product recalls or product liability or other claims being
brought against us. In responding to shortages, we may source components from alternative suppliers and
distributors. Quality issues associated with components from these alternative sources may lead to product failures
and associated costs notwithstanding our efforts to detect and remediate such quality issues. These issues could
harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers,
which could negatively impact our business, results of operations and financial condition.
Lack of key personnel could hurt our business.
Our products are very technical in nature, and we operate in a complex and competitive business environment. In
general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our
products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the
global nature of our business also requires that we have sophisticated and experienced staff to comply with
increasingly complex international laws and regulations. We face intense competition for these professionals from
our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job
market in Northern California, where many of our employees are located, is very competitive. If we do not offer
competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel,
which could impair our ability to properly run our business. We have experienced increased turnover since the start
of the COVID-19 pandemic, and this has continued as more employees return to the workplace from working
remotely. Our mandated COVID-19 vaccine policy in the Unites States also has resulted in a loss of personnel.
19
We may have higher than anticipated tax liabilities.
We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of
operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate.
The determination of our worldwide provision for income taxes and other tax liabilities requires estimation,
judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax
liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have
disagreed with our judgment in the past and may disagree with positions we take in the future resulting in
assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact
on our operating results and financial condition.
Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes
more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions
related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We
regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our
provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax
audits and any related litigation could be materially different from our historical income tax provisions and accruals.
Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our
earnings could adversely affect our financial position and results of operations.
On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and
Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax
on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies
continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make
adjustments to amounts previously reported that could materially impact our financial statements.
On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an
Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. Based on
our initial evaluation, we do not believe the Inflation Reduction Act will have a material impact on our income tax
provision and cash taxes. However, future U.S. Department of the Treasury guidance and regulations could result in
changes in this initial conclusion.
The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially
affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth
in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit
Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax
rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax
jurisdictions and the activities that give rise to a taxable presence in a particular country.
Environmental, health and safety regulations and enforcement proceedings may negatively impact our business,
results of operations and financial condition.
Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such
activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal
practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we
are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills,
disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise
impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by
third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of
our properties. We must also comply with various health and safety regulations in the United States and abroad in
connection with our operations.
20
We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and
possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the
future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other
releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where
we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future
obligations to comply with environmental or health and safety laws and regulations will not adversely affect our
business, results of operations or financial condition.
Our current and future debt and related covenants may restrict our future operations.
We have substantial debt and have the ability to incur additional debt. As of December 31, 2022, we had
approximately $1.2 billion of outstanding long-term indebtedness, primarily consisting of the 3.300% Senior Notes
due in March 2027 and the 3.700% Senior Notes due in March 2032 as further discussed in Note 6 of the
consolidated financial statements. In addition, we have a revolving credit facility that provides for up to $200.0
million in borrowing capacity, $0.2 million of which has been utilized for domestic standby letters of credit. Our
incurrence of substantial amounts of debt may have important consequences. For instance, it could:
• make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding
•
•
•
•
•
debt;
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and
principal due under our debt, which will reduce funds available for other business purposes;
increase our vulnerability to general adverse economic and industry conditions;
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we
operate;
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
limit our ability to obtain additional financing required to fund working capital and capital expenditures and
for other general corporate purposes.
Our existing credit facility, our Senior Notes and agreements we may enter in the future, contain or may contain
covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business
and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants
place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets
through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the
case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other
distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios,
including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test. Our
ability to comply with these covenants may be affected by events beyond our control, including prevailing
economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An
event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from
them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other
indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal
amount of our outstanding notes.
We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully
comply with such laws.
We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states
and foreign governments in which we conduct our business. These healthcare laws and regulations include, for
example:
•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from
soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce
either the referral of an individual for, or the purchase order or recommendation of, any item or services for
which payment may be made under a federal healthcare program such as the Medicare and Medicaid
programs;
21
• U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party
payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the false claims statutes;
•
•
•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices
and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information
Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic
healthcare transactions and protects the security and privacy of protected health information; and
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false
claims laws, which may apply to items or services reimbursed by any third-party payor, including
commercial insurers.
These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance
environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different
compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or
more of these requirements. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the
operation of our business. If our operations are found to be in violation of any of the laws described above or any
other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal
penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring
of our operations, any of which could adversely affect our ability to operate our business, results of operations and
financial condition.
Risks Related to Being a Public Company
Our failure to establish and maintain effective internal control over financial reporting could result in material
misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to
lose confidence in our reported financial information, which in turn could cause the trading price of our
common stock to decline.
Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary
for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting
have adversely affected us in the past and could affect us in the future, and the results of our periodic management
evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial
reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or
improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could
result in additional material weaknesses, result in material misstatements in our consolidated financial statements
and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause
the trading price of our common stock to decline.
22
General Business Risks
Natural disasters, climate related events, terrorist attacks, acts of war or other events beyond our control may
cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors
and customers, which could significantly impact our business, results of operations and financial condition.
We have significant manufacturing and distribution facilities, including in the western United States, France,
Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of
earthquakes, wildfires, floods, landslides and other natural disasters in recent years, some of which may be
associated with climate change. These occurrences could damage or destroy our facilities which may result in
interruptions to our business and losses that exceed our insurance coverage. In addition, lack of fuel resources due
to geo-political instability (such as Russia’s reduction in energy resources supplied to Western Europe), electricity
outages, the inability to operate our production and distribution facilities due to power grid failures or lack of fuel,
and strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts
of terrorism, bioterrorism, violence or war (such as Russia's invasion of Ukraine), weather-related events, or public
health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we
operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as
in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business,
results of operations and financial condition.
Risks Related to Our Common Stock
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions,
holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of
Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote.
In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are
entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining
directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able
to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us,
including the determination of business opportunities that may be suitable for our company. The Schwartz family
may exercise its control over us according to interests that are different from other investors’ or debtors’ interests.
In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a
change in control of our company.
The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the
ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more
favorable for disputes with the Company or the Company’s directors, officers or other employees.
Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within
the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district
court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding
brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any
director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action
arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of
Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a
claim against the Company or any of its directors, officers or other employees governed by the internal affairs
doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage
claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the
Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the
Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice
of forum provision contained in the Company’s bylaws to be inapplicable or unenforceable in an action, the
Company may incur additional costs associated with resolving such action in other jurisdictions.
23
Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the
Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by
the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply
to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act
creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created
by the Securities Act or the rules and regulations thereunder, subject to a limited exception for certain “covered
class actions.” There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the
choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by
operation of the Company’s choice of forum provision, to have waived claims arising under the federal securities
laws and the rules and regulations thereunder.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
We own our corporate headquarters located in Hercules, California. The principal manufacturing and research
locations for each segment are as follows:
Segment
Location
Owned/Leased
Life Science
Clinical Diagnostics
Shared
Boulder, Colorado
Oxford, England
Neuried, Germany
Shanghai, China
Suzhou, China
Irvine, California
Greater Seattle Area, Washington
Warsaw, Poland
Cressier, Switzerland
Dreieich, Germany
Greater San Francisco Bay Area, California
Ann Arbor, Michigan
Greater Paris Area, France
Lille, France
Leipzig, Germany
Singapore, Singapore
Leased
Leased
Leased
Leased
Leased
Leased
Leased
Leased
Owned/Leased
Owned/Leased
Owned/Leased
Leased
Leased
Owned
Leased
Leased
Most manufacturing and research facilities also house administration, sales and distribution activities. In addition,
we lease office and warehouse facilities in a variety of locations around the world. The facilities are used principally
for sales, service, distribution and administration for both segments.
24
ITEM 3. LEGAL PROCEEDINGS
We are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we
do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material
adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding
the ultimate outcome of these matters and their resolution could be material to our operating results for any
particular period, depending on the level of income for the period.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II.
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Information Concerning Common Stock
Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the ticker symbols
BIO and BIOb, respectively.
On February 14, 2023, we had 152 holders of record of Class A Common Stock and 90 holders of record of Class B
Common Stock. Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.
In November 2017, the Board of Directors authorized a share repurchase program ("Share Repurchase Program"),
granting the Company authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares
of our common stock. In both July 2020 and July 2022, the Board of Directors authorized increasing the Share
Repurchase Program to allow the Company to purchase up to an additional $200.0 million of stock, for a total
authorization of $650.0 million of stock. As of December 31, 2022, $207.4 million remained available under the
Share Repurchase Program.
The following table contains information on the shares of our common stock that we purchased or otherwise
acquired during the three months ended December 31, 2022, as required by the Securities and Exchange
Commission rules.
Period
Total Number of Shares
Purchased
Average Price Paid
per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number (or
Approximate Dollar Value)
of Shares that May yet be
Purchased Under the Plans
or Programs (in millions)
October 1 to October
31, 2022
—
—
—
$
November 1 to
November 30, 2022
December 1 to
December 31, 2022
241,408 Class A $
375.63
241,408 Class A $
—
—
—
$
298.1
207.4
207.4
See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for
securities authorized for issuance under equity compensation plans.
25
Stock Performance Graph
The following graph compares the cumulative stockholder returns over the past five years for our Class A Common
Stock, the S&P 500 Index, S&P 500 Life Sciences Tools & Services Index and a selected peer group, assuming
$100 invested on December 31, 2017, and reinvestment of dividends if paid:
S
R
A
L
L
O
D
350
300
250
200
150
100
50
2017
2018
2019
2020
2021
2022
Bio-Rad
S&P 500 Index
S&P 500 Life Sciences Tools & Services Index (2)
Peer Group (1) (2)
(1) The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher
Scientific, Meridian Bioscience and PerkinElmer.
(2) We are replacing the Peer Group with S&P 500 Life Sciences Tools & Services Index in the current fiscal year as
we believe that the latter is a better representation of our peer group due to significant consolidation in the sector
over the past few years. Both Peer Group and S&P 500 Life Sciences Tools & Services Index are presented for this
year of transition.
This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating
by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed
under these Acts.
ITEM 6. RESERVED
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
This discussion should be read in conjunction with the information contained in our consolidated financial
statements and the accompanying notes which are an integral part of the statements.
Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and
clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical
Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health
care specialists with products needed for clinical diagnostics.
We sell more than 12,000 products and services to a diverse client base comprised of scientific research, healthcare,
education and government customers worldwide. We do not disclose quantitative information about our different
products and services as it is impractical to do so based primarily on the numerous products and services that we sell
and the global markets that we serve.
26
We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex
chemical and biological materials and to identify, analyze and purify components. As our customers require
standardization for their experiments and test results, much of our revenues are recurring in nature.
We are impacted by the support of many governments for both research and healthcare. The current global
economic outlook is still uncertain as the need to control government social spending by many governments limits
opportunities for growth.
Approximately 41% of our 2022 consolidated net sales are derived from the United States and approximately 59%
are derived from international locations, with Europe being our largest international region. The international sales
are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British
Sterling. As a result, our consolidated net sales, which are expressed in U.S. dollars, are impacted by foreign
currency fluctuations. The impact of foreign currency fluctuations on cost of sales and operating expenses from our
international manufacturing sites and operations, which are mostly denominated in local currencies, is in the
opposite direction from the foreign currency impact on sales. We regularly discuss our changes in revenue and
expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if
notable, to explain the impact currency has on our results.
The consolidated financial statements as of December 31, 2021 and for the years ended December 31, 2021 and
2020 have been revised to correct prior period errors as discussed in Note 1, “Immaterial Correction to Previously
Issued Financial Statements” to our consolidated financial statements included in this Annual Report on Form 10-K.
Accordingly, Management’s Discussion and Analysis reflects the impact of those revisions.
COVID-19 and Supply Chain Impact
The full impact of the COVID-19 pandemic and related supply constraints continues to be inherently uncertain at
the time of this report. The COVID-19 pandemic has impacted and, we expect to some extent, will continue to
impact parts of our business, operations, financial condition and results of operations in a variety of ways. During
the fourth quarter of 2022, we saw continued but moderating demand for products associated with COVID-19
testing and related research. In addition, supply chain constraints and lockdowns in China have negatively impacted
sales, particularly instrument placements. While improving, we continue to experience delays and shortages in the
supply of certain components and raw materials. These shortages have caused a backlog of sales orders, some of
which we consider to be significant, and some delays in certain new product development activities. They have also
led to increases in inventory as we continue to receive available materials while we source those in short supply. We
made progress in reducing this backlog in the fourth quarter of 2022, and we anticipate normalizing the backlog
during 2023. For more discussion relating to the impacts of the COVID-19 pandemic, please see "Item 1A, Risk
Factors" to this Annual Report.
Acquisition
On August 3, 2022 (the "Acquisition Date"), we acquired all equity interests of Curiosity Diagnostics sp.z o.o.
("Curiosity") for a total consideration of $137.1 million, including the estimated fair value of contingent
consideration. The contingent consideration of up to $70.0 million is payable upon achievement of certain
technological development and sales-related milestones.
Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-
answer, rapid diagnostics PCR system for the molecular diagnostics market. The strategic rationale for the
transaction was to facilitate our entry into the molecular disease testing market with a differentiated platform. We
believe this acquisition will complement our Clinical Diagnostics product offerings. The acquisition was included in
our Clinical Diagnostics segment's results of operations from the Acquisition Date. The amount of acquisition-
related costs was not material.
27
Senior Notes due 2027 and 2032
In March 2022, pursuant to an indenture we issued $400.0 million in principal amount of Senior Notes due March
2027 (the “2027 Notes”) and $800.0 million in principal amount of Senior Notes due March 2032 (the “2032 Notes”
and, together with the 2027 Notes, the “Notes”). The issuance of the 2027 Notes yielded net cash proceeds of
$395.7 million at an effective rate of 3.5346% and the issuance of the 2032 Notes yielded net cash proceeds of
$790.5 at an effective rate of 3.8429%. The 2027 Notes and the 2032 Notes pay a fixed rate of interest of 3.3% and
3.7% per annum, respectively. Interest on the Notes is payable semi-annually in arrears on March 15 and September
15 of each year until the principal is paid or made available for payment.
Critical Accounting Policies and Estimates
The accompanying discussion and analysis of our financial condition and results of operations are based upon our
consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting
principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the
date of the financial statements and reported amounts of revenues and expenses during the reporting periods. We
evaluate our estimates on an on-going basis. We base our estimates on historical experience and on other
assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
However, future events may cause us to change our assumptions and estimates, which may require adjustment.
Actual results could differ from these estimates. We have determined that for the periods reported in this Annual
Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial
condition and results of operations.
Accounting for Income Taxes
We operate in multiple jurisdictions and our profits are taxed pursuant to the tax laws of these jurisdictions. Our
effective income tax rate may be affected by the changes in or interpretations of tax laws and tax agreements in any
given jurisdiction, utilization of net operating loss and tax credit carryforwards, changes in geographical mix of
income and expense, and changes in our assessment of matters such as the ability to realize deferred tax assets. As
a result of these considerations, we must estimate income taxes in each of the jurisdictions in which we operate.
This process involves estimating current tax exposure together with assessing temporary differences resulting from
the different treatment of items for tax and accounting purposes. These differences result in deferred tax assets and
liabilities, which are included in the consolidated balance sheet.
We assess the likelihood that our deferred tax assets will be recovered from future taxable income, considering all
available evidence such as historical levels of income, expectations and risks associated with estimates of future
taxable income and ongoing prudent and feasible tax strategies. When we determine that it is not more likely than
not that we will realize all or part of our deferred tax assets, an adjustment is charged to earnings in the period when
such determination is made. Likewise, if we later determine that it is more likely than not that all or a part of our
deferred tax assets would be realized, the previously provided valuation allowance would be reversed.
We make certain estimates and judgments about the application of tax laws, the expected resolution of uncertain tax
positions and other matters surrounding the recognition and measurement of uncertain tax benefits. In the event that
uncertain tax positions are resolved for amounts different than our estimates, or the related statutes of limitations
expire without the assessment of additional income taxes, we will be required to adjust the amounts of the related
assets and liabilities in the period in which such events occur. Such adjustments may have a material impact on our
income tax provision and our results of operations.
28
Business Acquisitions
Accounting for business acquisitions requires us to make significant estimates and assumptions, especially at the
acquisition date with respect to tangible and intangible assets acquired and liabilities assumed and pre-acquisition
contingencies. In a business combination, we allocate the purchase price to the acquired business’ identifiable assets
and liabilities at their acquisition date fair values. The excess of the purchase price over the amount allocated to the
identifiable assets and liabilities, if any, is recorded as goodwill.
The assets acquired and liabilities assumed in our business combinations consist of acquired working capital and
finite-lived and indefinite-lived intangible assets. The carrying value of acquired working capital approximates its
fair value, given the short-term nature of these assets and liabilities. We estimate the fair value of finite-lived and
indefinite-lived intangible assets acquired using a discounted cash flow approach, which includes an analysis of the
future cash flows expected to be generated by such assets and the risk associated with achieving such cash flows.
The key assumptions used in the discounted cash flow model include the discount rate that is applied to the
discretely forecasted future cash flows to calculate the present value of those cash flows and the estimate of future
cash flows attributable to the acquired intangible assets, which include revenue, operating expenses and taxes. Our
estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may
be up to one year from the acquisition date, we may record adjustments to the fair value of assets acquired and
liabilities assumed, with the corresponding offset to goodwill.
Impairment of Goodwill
We conduct a goodwill impairment analysis annually in the fourth quarter or more frequently if indicators of
impairment exist or if a decision is made to sell or exit a business. We test goodwill at the reporting unit level.
Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may
include deterioration in general economic conditions, negative developments in equity and credit markets, adverse
changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings
and cash flows, a trend of negative or declining cash flows, a decline in actual or planned revenue or earnings
compared with actual and projected results of relevant prior periods, or other relevant entity-specific events such as
changes in management, key personnel, strategy or customers, contemplation of bankruptcy, or litigation. The fair
value that could be realized in an actual transaction may differ from that used to evaluate the impairment of
goodwill.
We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit
is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative
goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if
we elect to bypass the qualitative assessment, goodwill is tested at the reporting unit level using a quantitative
impairment test. There were no impairments for the years ended December 31, 2022, 2021 and 2020.
Revenue Recognition
We recognize revenue from operations through the sale of products, services, license of intellectual property and
rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised
products or services to customers in an amount that reflects the consideration we expect to receive in exchange for
those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added
tax, etc.), which are subsequently remitted to government authorities.
We enter into contracts that can include various combinations of products and services, which are generally
accounted for as distinct performance obligations. A product or service is considered distinct if it is separately
identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service
on its own or with other resources that are readily available to the customer. The transaction consideration is
allocated between separate performance obligations of an arrangement based on the stand-alone selling price
(“SSP”) for each distinct product or service.
29
We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by
transferring control of the product to the customer. We use judgment to evaluate whether and when control has
transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and
customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For
products that include installation, the product and installation are separate performance obligations. The product
revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service
revenue is recognized when the product installation is completed.
At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered
variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the
estimated amount of product returns.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a
stand-ready performance obligation. For arrangements that include a combination of products and services, the
transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used
to determine the stand-alone selling prices for product and service revenues is based on the observable prices when
the product or services have been sold separately.
We recognize revenues for a functional license of intellectual property at a point in time when the control of the
license and technology transfers to the customer. For license agreements that include sales or usage-based royalty
payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the
performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially
satisfied.
The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of
purchasing our products and services, not to either provide or receive financing to or from our customers. We record
contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length
of one year or less. Our payment terms vary by the type and location of our customer, and the products and services
offered. The term between invoicing and when payment is due is not significant.
Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on
a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as
well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract
commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease
classification as either an operating or sales-type lease. The lease term used in performing the lease classification
test, includes the noncancellable period of the lease together with those periods covered by lease extension options
if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the
customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not
terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term
for reagent rental agreements, including the impact from any associated contractual termination penalties, are
subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee
to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term
has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee
to purchase the underlying asset.
30
Fair Value Measurements
U.S. GAAP establishes three levels of inputs that may be used to measure fair value. Each level of input has
different levels of subjectivity and difficulty involved in determining fair value. Valuation of Level 1 and 2
instruments generally do not require significant management judgment and the estimation is not difficult. Level 3
instruments include unobservable inputs that are supported by little or no market activity and that are significant to
the fair value of the assets or liabilities. The determination of fair value for Level 3 instruments requires the most
management judgment and subjectivity.
We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to Sartorius-
Herbst Beteiligungen II GmbH to simplify the accounting. The Loan includes certain value appreciation rights that
are due upon repayment of the Loan. The fair value of the Loan and value appreciation right is estimated under the
income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value
measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an
estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair
value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and
expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially
differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in
expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and
value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market
value of equity securities and loan receivable in our consolidated statements of income (loss).
Results of Operations - Sales, Gross Margins and Expenses
Comparison of the Year Ended December 31, 2022 to the Year Ended December 31, 2021
The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:
Net sales
Cost of goods sold
Gross profit
Selling, general and administrative expense
Research and development expense
Net (loss) income
Net sales
2022
2021
100.0 %
44.1
55.9
29.5
9.2
(129.5)
100.0 %
43.9
56.1
30.0
8.9
145.6
Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local
currency using the current period monthly average foreign exchange rates for that currency and comparing that to
current period sales.
Net sales (sales) for the year ended December 31, 2022 were $2.80 billion, compared to $2.92 billion for the year
ended December 31, 2021, a decrease of 4.1%. COVID-related sales were approximately $109.2 million for the
year ended December 31, 2022 compared to approximately $265.7 million for the year ended December 31, 2021.
On a currency neutral basis, for the year ended December 31, 2022 sales increased by approximately 0.3%
compared to the same period in 2021. Currency neutral sales increased in the Americas, partially offset by decreases
in both Asia Pacific and Europe. Sales for the year ended December 31, 2021 were elevated due to the
approximately $31.6 million of royalty revenue related to an intellectual property settlement. Excluding COVID-
related sales and the impact of royalty revenue related to an intellectual property litigation settlement in 2021, sales
increased 7.2% on a currency neutral basis from the year ended December 31, 2021.
31
The Life Science segment sales for the year ended December 31, 2022 were $1.35 billion, a decrease of 3.8%
compared to the year ended December 31, 2021. On a currency neutral basis, sales increased 0.3% compared to the
year ended December 31, 2021. The currency neutral sales increase was primarily attributed to strong growth of
Process Chromatography, Western Blotting, and Antibody products, partially offset by lower qPCR product sales
due to the decline in COVID-19 related demand. Currency neutral sales increased in the Americas and Asia Pacific,
while EMEA sales declined. Sales in 2021 also benefited from the $31.6 million royalty revenue related to an
intellectual property litigation settlement. Excluding COVID-related sales and the impact of royalty revenue related
to an intellectual property litigation settlement in 2021, sales increased 15.2% on a currency neutral basis from the
year ended December 31, 2021.
The Clinical Diagnostics segment sales for the year ended December 31, 2022 were $1.45 billion, a decrease of
4.3% compared to the year ended December 31, 2021. On a currency neutral basis, sales increased 0.4% compared
to the year ended December 31, 2021. The currency neutral sales increase was primarily driven by growth in
Quality Controls and Blood Typing products, especially in Europe and the Americas, despite supply chain
constraints having an impact on instrument placements. The increase in currency neutral sales was partially offset
by the impact of COVID lockdowns in China during the second, third, and fourth quarters of 2022. Excluding
COVID-related sales, sales increased 1.3% on a currency neutral basis from the year ended December 31, 2021.
Gross margin
Consolidated gross margins were 55.9% for the year ended December 31, 2022 compared to 56.1% for the year
ended December 31, 2021. Life Science segment gross margins for the year ended December 31, 2022 decreased by
approximately 1.6 percentage points from the year ended December 31, 2021. The decrease in gross margins was
primarily driven by higher logistics costs and product mix. The 2021 Life Science margins also benefited from the
$31.6 million royalty revenue related to an intellectual property litigation settlement. Clinical Diagnostics segment
gross margins for the year ended December 31, 2022 increased by approximately 1.2 percentage points compared to
the year ended December 31, 2021. The increase in gross margins was primarily driven by a one-time restructuring
expense related to the 2021 restructuring plan that was announced and recorded in the first quarter of 2021 and the
strong US dollar, partially offset by higher logistics costs and product mix.
Selling, general and administrative expense
Consolidated selling, general and administrative expenses (SG&A) decreased to $827.8 million or 29.5% of sales
for the year ended December 31, 2022 compared to $877.1 million or 30.0% of sales for the year ended
December 31, 2021. The decrease in SG&A was primarily driven by a one-time restructuring expense related to the
2021 restructuring plan that was announced and recorded in the first quarter of 2021, as well as by lower employee
related expenses.
Research and development expense
Consolidated research and development (R&D) expenses decreased to $256.9 million or 9.2% of sales for the year
ended December 31, 2022 compared to $260.6 million or 8.9% of sales for the year ended December 31, 2021. Life
Science segment R&D expense increased for the year ended December 31, 2022, compared to the year ended
December 31, 2021, primarily from increased personnel costs from the Dropworks, Inc. acquisition in October of
2021, and increased investment to complete strategic projects in key investment areas. Clinical Diagnostics segment
R&D expense decreased for the year ended December 31, 2022 from the year ended December 31, 2021, primarily
due to a one-time restructuring expense related to the 2021 restructuring plan that was announced and recorded in
the first quarter of 2021, partially offset by continued investment in new strategic development projects and
increased personnel costs from the Curiosity Diagnostics acquisition.
32
Results of Operations – Non-operating
Interest expense
Interest expense for the years ended December 31, 2022 and 2021 was $38.1 million and $1.6 million, respectively,
an increase of $36.6 million compared to the prior year period. The increase was primarily due to the issuance of
$1.2 billion Senior Notes in March 2022.
Foreign currency exchange gains and losses
Foreign currency exchange (gains) and losses consist primarily of foreign currency transaction gains and losses on
intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts
used to manage our foreign currency exchange risk. Foreign currency exchange net gains were $0.2 million for the
year ended December 31, 2022 compared to net losses of $2.8 million for the year ended December 31, 2021. Gains
and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany
debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.
Change in fair market value of equity securities and loan receivable
(Gains) losses from change in fair market value of equity securities and loan receivable was a loss of $5.19 billion
and a gain of $4.93 billion for the years ended December 31, 2022 and 2021, respectively. The change in the fair
market value primarily resulted from the recognition of holding losses of $5.07 billion compared to holding gains of
$4.92 billion primarily for our investment in Sartorius AG, for the years ended December 31, 2022 and 2021,
respectively. In addition, there were losses of $100.6 million and $10.8 million for the years ended December 31,
2022 and 2021, respectively, for the change in fair market value of the Loan entered into with SHB.
Other (income), net
Other (income), net includes investment and dividend income, interest income on our cash and cash equivalents,
short-term investments and long-term marketable securities. Other (income), net for the year ended December 31,
2022 increased to $44.6 million compared to $26.8 million for the year ended December 31, 2021. The difference of
income of $17.8 million was primarily due to $12.6 million increase in the Sartorius AG dividends declared during
the year ended December 31, 2022, compared with the year ended December 31, 2021, and an increase in our
investment income primarily attributable to an increase in our investments as a result of cash invested from the $1.2
billion Senior Notes issued in March 2022 and higher interest rates during 2022. This was partially offset by an
increase in both, other than temporary impairment losses of $11.1 million and current expected credit losses on
loans of $7.5 million in entities in which we have equity method investments.
Effective tax rate
Our effective tax rates were 22.9% and 21.9% for the years ended December 31, 2022 and 2021, respectively. The
effective tax rates for the years ended December 31, 2022 and 2021 were primarily driven by the unrealized gain/
loss in equity securities that was taxed at 22.5% and 22.4%, respectively, as well as the geographical mix of
earnings.
Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently
under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations,
and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of
deductions and allocations of income among various tax jurisdictions.
We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the
resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements,
although an adverse resolution of one or more of these uncertain tax positions in any period may have a material
impact on the results of operations for that period.
33
As of December 31, 2022, based on the expected outcome of certain examinations or as a result of the expiration of
statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible
that our previously unrecognized tax benefits could decrease by approximately $22.2 million.
On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an
Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. Based on
our initial evaluation, we do not believe the Inflation Reduction Act will have a material impact on our income tax
provision and cash taxes. We continue to monitor the changes in tax laws and regulations to evaluate their potential
impact on our business.
Comparison of the Year Ended December 31, 2021 to the Year Ended December 31, 2020
The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:
Net sales
Cost of goods sold
Gross profit
Selling, general and administrative expense
Research and development expense
Net (loss) income
Net sales
2021
2020
100.0 %
43.9
56.1
30.0
8.9
145.6
100.0 %
43.5
56.5
31.4
8.6
149.8
Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local
currency using the current period monthly average foreign exchange rates for that currency and comparing that to
current period sales.
Net sales (sales) for the year ended December 31, 2021 were $2.92 billion, compared to $2.55 billion for the year
ended December 31, 2020, an increase of 14.8%. Excluding the impact of foreign currency, for the year ended
December 31, 2021 sales increased by approximately 12.7% compared to the year ended December 31, 2020.
Currency neutral sales increased in all regions, led by growth in Asia Pacific and Europe. Excluding the impact of
COVID related sales, currency neutral sales increased by 17% compared to the year ended December 31, 2020.
The Life Science segment sales for the year ended December 31, 2021 were $1.40 billion, an increase of 13.7%
compared to the year ended December 31, 2020. On a currency neutral basis, sales increased 12.0% compared to the
year ended December 31, 2020. Currency neutral sales were up in nearly all product lines but were primarily driven
by growth in our Western Blotting, Digital PCR, and Process Chromatography products. A significant portion of the
Life Science segment growth came from products used to support COVID-19 research and testing. All regions
experienced double digit currency neutral sales growth compared to the year ended December 31, 2020.
The Clinical Diagnostics segment sales for the year ended December 31, 2021 were $1.52 billion, an increase of
16.1% compared to the year ended December 31, 2020. On a currency neutral basis, sales increased 13.6%
compared to the year ended December 31, 2020. Currency neutral sales increased across all product lines and
regions as the overall diagnostics market continues to recover from the COVID-19 pandemic, including an increase
in utilization in lab operations.
34
Gross margin
Consolidated gross margins were 56.1% for the year ended December 31, 2021 compared to 56.5% for the year
ended December 31, 2020. Life Science segment gross margins for the year ended December 31, 2021 increased by
approximately 0.5 percentage points compared to the year ended December 31, 2020, primarily related to increased
sales volume, favorable product mix related to higher sales of Digital PCR and Process Chromatography products,
and lower production costs. Clinical Diagnostics segment gross margins for the year ended December 31, 2021
decreased by approximately 1.1 percentage points compared to the year ended December 31, 2020. The decrease in
the Clinical Diagnostics segment gross margins for the year ended December 31, 2021 was primarily related to the
costs associated with the restructuring plan announced in February 2021, partially offset by increased sales for the
year ended December 31, 2021.
Selling, general and administrative expense
Consolidated selling, general and administrative expenses (SG&A) increased to $877.1 million or 30.0% of sales for
the year ended December 31, 2021 compared to $798.8 million or 31.4% of sales for the year ended December 31,
2020. The increase to SG&A was primarily related to the restructuring plan announced in February 2021, as well as
increased employee related expenses.
Research and development expense
Research and development (R&D) expense increased to $260.6 million or 8.9% of sales for the year ended
December 31, 2021 compared to $217.8 million or 8.6% of sales for the year ended December 31, 2020. R&D
expense increased for the year ended December 31, 2021 compared to the year ended December 31, 2020, in both
the Life Science and Clinical Diagnostics segment. The increase was primarily from increases in investment in
strategic projects and research initiatives, costs related to the restructuring plan announced in February 2021, and
higher employee related expenses.
Results of Operations – Non-operating
Interest expense
Interest expense for the years ended December 31, 2021 and 2020 was $1.6 million and $21.9 million, respectively,
a decrease of $20.3 million primarily due to the repayment of the $425.0 million principal amount of Senior Notes
in December 2020.
Foreign currency exchange gains and losses
Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on
intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts
used to manage our foreign currency exchange risk. Foreign currency exchange net losses for the years ended
December 31, 2021 and 2020 were $2.8 million and $1.8 million, respectively. Gains and losses are primarily due to
the estimating process inherent in the timing of product shipments and intercompany debt payments, market
volatility, and the change in the fair value of our foreign exchange contracts.
Change in fair market value of equity and debt securities
Change in fair market value of equity and debt securities were gains of $4.93 billion for the year ended December
31, 2021 compared to $4.50 billion for the year ended December 31, 2020, primarily resulting from the recognition
of holding gains on our position in Sartorius AG of $4.92 billion in 2021 and $4.48 billion in 2020, partially offset
by a decrease in fair value of a loan to Sartorius-Herbst Beteiligungen II GmbH of $10.8 million.
35
Other (income), net
Other (income), net includes investment and dividend income, interest income on our cash and cash equivalents,
short-term investments and long-term marketable securities. Other (income), net for the year ended December 31,
2021 increased to $26.8 million compared to $24.5 million for the year ended December 31, 2020. Other (income),
net increased primarily due to a $10.1 million increase in the Sartorius AG dividends declared in 2021, and an
increase in investment and other income of $3.9 million, partially offset by a gain of $11.7 million on the sale of our
Informatics division in 2020.
Effective tax rate
Our effective tax rates were 21.9% and 22.4% for the years ended December 31, 2021 and 2020, respectively. The
effective tax rates for the years ended December 31, 2021 and 2020 were primarily driven by the unrealized gain in
equity securities that is taxed at approximately 22% as well as the geographic mix of earnings and the taxation of
our foreign earnings. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many
factors including, but not limited to, changes in the geographic mix of earnings, changes to statutory tax rates,
changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.
Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently
under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations,
and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of
deductions and allocations of income among various tax jurisdictions. We do not believe any currently pending
uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an
adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the
results of operations for that period.
We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the
resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements,
although an adverse resolution of one or more of these uncertain tax positions in any period may have a material
impact on the results of operations for that period.
As of December 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of
statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible
that our previously unrecognized tax benefits could decrease by approximately $20.8 million. Substantially all such
amounts will impact our effective income tax rate.
36
Liquidity and Capital Resources
Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the
markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local
distribution facilities around the world. Our product mix is diversified, and certain products compete largely on
product efficacy, while others compete on price. Gross margins are generally sufficient to exceed normal operating
costs, and funding for research and development of new products, as well as routine outflows for capital
expenditures, interest and taxes. In addition to the annual positive cash flow from operating activities, additional
liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured
revolving credit facility (Credit Agreement, as amended) that we entered into in April 2019, and to a lesser extent
international lines of credit. Borrowings under the Credit Agreement, as amended, are available on a revolving basis
and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We
had no outstanding borrowings under the 2019 Credit Agreement, as amended, as of December 31, 2022, however,
$0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability. In March
2022, we issued $400 million aggregate principal amount of 3.3% Senior Notes due 2027, and $800 million
aggregate principal amount of 3.7% Senior Notes due 2032. Net cash proceeds from the bond issuance after
deducting the underwriting discount and estimated offering expenses was $1.186 billion. Interest on the Notes is
payable semiannually in arrears on March 15 and September 15 of each year until the principal is paid or made
available for payment. Management believes that this availability, together with cash flow from operations, will be
adequate to meet our current objectives for operations, research and development, capital additions for
manufacturing and distribution, plant and equipment, information technology systems and acquisitions of
reasonable proportion to our existing total available capital.
At December 31, 2022, we had available $1.8 billion in cash, cash equivalents and short-term investments, of which
approximately 13% was held in our foreign subsidiaries. The amount of funds held in the United States can
fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons,
such as acquisitions and borrowings. As part of our ongoing liquidity assessments, we regularly monitor the mix of
domestic and foreign cash flows (both inflows and outflows).
It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not
restricted by local laws or accounting rules, and there are no substantial incremental costs.
Comparison of the Year Ended December 31, 2022 to the Year Ended December 31, 2021
Cash Flows from Operations
Net cash provided by operations was $194.4 million and $669.5 million for the years ended December 31, 2022 and
2021, respectively. The decrease of $475.1 million was primarily due to lower cash received from customers, higher
cash paid to suppliers and to employees, higher income taxes paid, and interest paid on the Notes in 2022. These
decreases were partially offset by higher proceeds from foreign exchange contracts and higher dividends in 2022
compared to 2021.
Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth
quarter sales commissions and annual employee bonuses, and we expect this pattern to recur in the first quarter of
2023.
Cash Flows from Investing Activities
Our investing activities have consisted primarily of cash used for purchases of marketable securities and
investments, and acquisitions.
37
Net cash used in investing activities was $1,207.6 million and $797.4 million for the years ended December 31,
2022 and 2021, respectively. The increase of cash used for investing activities of $410.2 million was primarily
attributable to the purchase of marketable securities and investments utilizing the cash proceeds from the sale of the
senior notes as described below. The increase was partially offset by a $453.4 million funding for a collateralized
loan to Sartorius-Herbst Beteiligungen II GmbH in 2021, lower capital expenditures, and lower net cash outflows
for the acquisition of Curiosity in 2022 compared to the acquisition of Dropworks in 2021.
Cash Flows from Financing Activities
Our financing activities have consisted primarily of cash from the issuance of senior notes.
Net cash provided by financing activities was $973.6 million compared to cash used for financing activities of $55.4
million for the years ended December 31, 2022 and 2021, respectively. This increase was primarily attributable to
the net cash proceeds from the Notes. The increase was partially offset by a higher repurchase of our common stock
by $165.7 million in 2022 than in 2021 as described below.
Treasury Shares
During the year ended December 31, 2022, 135,744 shares of Class A treasury stock with an aggregate total cost of
$58.4 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the
Class A treasury stock, a gain of $0.4 million was incurred as they were reissued at a higher price than their average
cost, which increased Retained earnings, while $51.8 million reduced Additional paid-in capital.
During the year ended December 31, 2021, 114,711 shares of Class A treasury stock with an aggregate total cost of
$43.6 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the
Class A treasury stock, a loss of $6.7 million was incurred as they were reissued at a lower price than their average
cost, which reduced Retained earnings, while $37.0 million reduced Additional paid-in capital.
The re-issuance of the treasury stock for the years ended December 31, 2022 and 2021 did not require cash
payments or receipts and therefore did not affect liquidity.
During the year ended December 31, 2022, we repurchased 496,692 shares of Class A common stock for $215.7
million under our Share Repurchase Program, compared to the repurchase of 86,506 shares of our common stock
for $50.0 million during the year ended December 31, 2021. As of December 31, 2022, $207.4 million of stock
remained available for repurchases under the Company's current Share Repurchase Program. We designated these
repurchased shares as treasury stock.
Comparison of the Year Ended December 31, 2021 to the Year Ended December 31, 2020
At December 31, 2021, we had available $869.9 million in cash, cash equivalents and short-term investments, of
which approximately 23% was held in our foreign subsidiaries. The amount of funds held in the United States can
fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons,
such as acquisitions. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and
foreign cash flows (both inflows and outflows).
It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not
restricted by local laws or accounting rules, and there are no substantial incremental costs.
Demand for our products and services could change more dramatically in the short-term than in previous years due
to the impacts of the COVID-19 pandemic, as well as due to funding, reimbursement constraints and support levels
from government, universities, hospitals and private industry, including diagnostic laboratories. The need for certain
sovereign nations with large annual deficits to curtail spending, international trade disputes and increased
regulation, could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying
payment for goods and services or renegotiating their debts could impact our liquidity.
38
Cash Flows from Operations
Net cash provided by operations was $669.5 million and $584.9 million for the years ended December 31, 2021 and
2020, respectively. The net increase between the year ended December 31, 2021 and the year ended December 31,
2020 of $84.6 million was primarily due to higher cash received from customers as a result of the growth in sales,
higher Sartorius AG dividends in 2021 compared to 2020, lower interest paid as a result of the repayment of the
$425.0 million principal amount of Senior Notes in December 2020, proceeds from forward foreign exchange
contracts in 2021 compared to payments for forward foreign exchange contracts in 2020, and higher investment
income received in 2021 than in 2020. These increases were partially offset by higher cash paid to suppliers
primarily for materials to support the increase in sales, cash paid for employee related expenses such as salaries,
bonuses and benefits, and to a lesser extent for employee restructuring programs. The increases were also partially
offset by higher income taxes paid.
Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth
quarter sales commissions and annual employee bonuses, and we expect this pattern to recur in the first quarter of
2022.
Cash Flows from Investing Activities
Our investing activities consisted primarily of cash used for extending a collateralized loan, activity related to the
purchases, sales and maturities of marketable securities, acquisitions and capital expenditures.
Net cash used in investing activities was $797.4 million and $69.9 million for the years ended December 31, 2021
and 2020, respectively. The increase of $727.5 million was primarily attributable to a $453.4 million funding for a
collateralized loan to Sartorius-Herbst Beteiligungen II GmbH, an increase of $204.3 million for net cash outflows
from purchases, sales and maturities of marketable securities and investments, higher net cash outflows of $28.9
million for the acquisition of Dropworks, Inc. in 2021 compared to the acquisition of Celsee, Inc. in 2020, net
payments of $25.2 million for higher capital expenditures, and proceeds of $12.2 million from a divestiture of a
division that was received in 2020 compared to none in 2021.
Cash Flows from Financing Activities
Our financing activities have consisted primarily of cash used for repayment of debt, purchases of treasury stock,
payments for contingent consideration, and cash proceeds from the issuance of common stock for share-based
compensation.
Net cash used in financing activities was $55.4 million compared to $523.0 million for the years ended
December 31, 2021 and 2020, respectively. This decrease was primarily attributable to the repayment of the $425
million principal amount of Senior Notes in 2020, and lower purchases of treasury stock in 2021 compared to 2020
of $50.0 million.
Treasury Shares
During the year ended December 31, 2021, 114,711 shares of Class A treasury stock with an aggregate total cost of
$43.6 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the
Class A treasury stock, a loss of $6.7 million was incurred as they were reissued at a lower price than their average
cost, which reduced Retained earnings, while $37.0 million reduced Additional paid-in capital.
During the year ended December 31, 2020, 117,423 shares of Class A treasury stock with an aggregate total cost of
$38.5 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the
Class A treasury stock, a loss of $9.0 million was incurred as they were reissued at a lower price than their average
cost, which reduced Retained earnings, while $29.5 million reduced Additional paid-in capital.
39
The re-issuance of the treasury stock for the years ended December 31, 2021 and 2020 did not require cash
payments or receipts and therefore did not affect liquidity.
During the year ended December 31, 2021, we repurchased 89,506 shares of Class A common stock for $50.0
million under our Share Repurchase Program, compared to the repurchase of 291,941 shares of our common stock
for $100.0 million during the year ended December 31, 2020. As of December 31, 2021, $223.1 million remained
under the Share Repurchase Program. We designated these repurchased shares as treasury stock.
Contractual Obligations
The following summarizes certain of our contractual obligations as of December 31, 2022 and the effect such
obligations are expected to have on our cash flows in future periods (in millions):
Contractual Obligations
Long-term debt, including
current portion (1)
Interest payments (1)
Operating lease obligations (2)
Purchase obligations (3)
Long-term liabilities (4)
$
$
$
$
$
Total
1,210.6 $
335.2 $
216.4 $
17.2 $
123.0 $
Payments Due by Period
Less
Than
One Year
1-3
Years
3-5
Years
More
than
5 Years
0.5 $
43.6 $
43.6 $
17.1 $
4.6 $
1.0 $
87.0 $
68.8 $
0.1 $
35.4 $
400.9 $
76.4 $
46.5 $
— $
47.8 $
808.2
128.2
57.5
—
35.2
(1) These amounts represent expected cash payments, primarily from Senior Notes, which are included in our December 31, 2022
consolidated balance sheet. See Note 6 of the consolidated financial statements for additional information about our debt.
(2) Operating lease obligations are described in Note 17 of the consolidated financial statements.
(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify
all significant terms. Purchase obligations exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs
when products or services are delivered to Bio-Rad.
(4) These amounts primarily represent recognized long-term obligations for other post-employment benefits and long-term deferred revenue.
Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $74.9 million. We are not able to
reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table
above. See Note 7 of the consolidated financial statements for additional information about our income taxes.
Recent Accounting Pronouncements Adopted
See Note 1 to the consolidated financial statements for recent accounting pronouncements adopted and to be
adopted.
40
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Financial Risk Management
The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows
arising from unexpected foreign exchange rate and interest rate changes. Financial exposures are managed through
operational means and by using various financial instruments, including cash and investments, borrowings, and
forward and spot foreign exchange contracts. No derivative financial instruments are entered into for the purpose of
trading or speculation. Company policy requires that all derivative positions are undertaken to manage the risks
arising from underlying business activities. We do not have derivative contracts that are designated for hedge
accounting treatment. As a result, all derivative instruments are carried at fair value on the balance sheet and
changes in fair value are included in reported earnings.
Foreign Exchange Risk. We operate and conduct business in many countries and are exposed to movements in
foreign currency exchange rates. We face transactional currency exposures that arise when we enter into
transactions denominated in currencies other than U.S. dollars. Additionally, our consolidated net equity is impacted
by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S.
dollar.
Foreign currency exposures are managed and hedged on a centralized basis. This allows for natural offsets and
netting of foreign exchange exposures across entities. Where possible, we seek to manage our foreign exchange risk
in part through operational means, including matching same-currency revenues to same-currency costs, and same-
currency assets to same-currency liabilities. We enter into foreign currency forward contracts to hedge the gains and
losses arising from remeasurement of non-US dollar denominated monetary assets and liabilities, primarily cash,
accounts receivables and accounts payables. The majority of forward contracts expire within 90 days or less. We
record the change in value of our foreign currency denominated cash, receivables and payables as a Foreign
exchange (gain) loss on our consolidated statements of income along with the change in fair market value of the
forward exchange contract used as an economic hedge of those assets or liabilities.
Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign
currency exchange rates. All other variables were held constant. Market risk associated with derivative holdings is
the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange
rates. A hypothetical 10% depreciation / appreciation of foreign currencies relative to the U.S. dollar would result in
an unrealized gain / loss of $43.5 million on our derivative position as of December 31, 2022. The gains or losses on
foreign currency forward contracts resulting from changes in currency exchange rates are expected to approximately
offset losses or gains on the exposures being hedged. This impact of a change in exchange rates excludes the offset
derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect
significantly.
Interest Rate Risk of Debt Instruments. Bio-Rad centrally manages the short-term cash surpluses and shortfalls of
its subsidiaries. Our holdings of variable rate debt instruments at year-end were analyzed to determine their
sensitivity to movements in interest rates. Due to the relatively small amount of short-term variable rate debt
instruments we have outstanding, there would not be a material impact to earnings or cash flows if interest rates
moved adversely by 10%. Our holdings of long-term debt instruments consist primarily of fixed-rate instruments
and are thus insulated from interest rate changes. As of December 31, 2022, the overall interest rate risk associated
with our debt instruments was not significant.
Share price movement risk associated with our investment in Sartorius. We face financial statement exposure
resulting from changes in the market value of our position in Sartorius. A 10% depreciation / appreciation on the
quoted stock prices for ordinary and preference shares of Sartorius at December 31, 2022, would result in an
approximate loss / gain of $0.85 billion reported in the financial statement line (Gains) losses from change in fair
market value of equity securities and loan receivable in our consolidated statements of income (loss) for the year
ended December 31, 2022.
41
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Index to Consolidated Financial Statements
Reports of Independent Registered Public Accounting Firm
Consolidated Balance Sheets at December 31, 2022 and 2021
Consolidated Statements of Income (Loss) for each of the three years in the period ended
December 31, 2022
Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the
period ended December 31, 2022
Consolidated Statements of Cash Flows for each of the three years in the period ended
December 31, 2022
Consolidated Statements of Changes in Stockholders’ Equity for each of the three years
in the period ended December 31, 2022
Notes to Consolidated Financial Statements
Page
43
46
48
49
50
51
52
42
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio-Rad Laboratories, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the
Company) as of December 31, 2022 and 2021, the related consolidated statements of income (loss), comprehensive
income (loss), changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended
December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the
consolidated financial statements present fairly, in all material respects, the financial position of the Company as of
December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-
year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based
on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission, and our report dated February 17, 2023 expressed an unqualified
opinion on the effectiveness of the Company's internal control over financial reporting.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is
to express an opinion on these consolidated financial statements based on our audits. We are a public accounting
firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of
material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks
of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the
amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated
financial statements that was communicated or required to be communicated to the audit committee and that: (1)
relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
accounts or disclosures to which it relates.
Assessment of Lease Term for Reagent Rental Arrangements
As discussed in Note 1 to the consolidated financial statements, the Company earns revenue from reagent
rental agreements with its customers. Each agreement generally includes lease elements subject to the lease
accounting standards and non-lease elements subject to the revenue accounting standards. The classification
of the lease component as an operating or sales-type lease can impact the timing of revenue recognition and
cost attributable to the underlying lease elements. While most reagent rental arrangements contain an option
43
for a lessee to extend or cancel the agreement, or both, the period in which the contract is enforceable is
short, and the lease term has been determined to be the noncancelable period. The revenue allocated to the
reagent rental lease elements was approximately 3% of total revenue for the year ended December 31, 2022
and it is included as part of Net Sales in the consolidated statements of income (loss).
We identified the assessment of the lease term for reagent rental agreements, including the impact from any
associated contractual termination penalties, as a critical audit matter. The Company’s determination of
lease classification as operating or sales-type lease is primarily dependent on the initial determination of the
lease term. The Company’s process is based on the manual examination of a high volume of agreements
that are negotiated individually across the world with diverse terms. Testing the determination of the lease
term, including consideration of contractual termination penalties, required a high degree of auditor
judgment to design and execute the audit procedures.
The following are the primary procedures we performed to address this critical audit matter. We evaluated
the design and tested the operating effectiveness of certain internal controls related to the Company’s lease
classification process. This included controls related to the Company’s process for determining the lease
term including consideration of contractual termination penalties. We assessed the Company’s policy for
determining that the lease term of its reagent rental arrangements was in accordance with U.S generally
accepted accounting principles. Additionally, for a selection of reagent rental agreements, we read the
underlying contract, and compared relevant terms within the contract to the Company’s determination of
lease term analysis and evaluated management’s judgment on the determination of the length of the lease
term. We evaluated the sufficiency of the evidence obtained by assessing the results of procedures
performed, including the appropriateness of the nature and extent of such evidence.
/s/ KPMG LLP
We have served as the Company's auditor since 2013.
Santa Clara, California
February 17, 2023
44
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio-Rad Laboratories, Inc.:
Opinion on Internal Control Over Financial Reporting
We have audited Bio-Rad Laboratories, Inc. and subsidiaries' (the Company) internal control over financial reporting as of
December 31, 2022, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control –
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated
statements of income (loss), comprehensive income (loss), changes in stockholders' equity, and cash flows for each of the years
in the three-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements),
and our report dated February 17, 2023 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report
on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control
over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ KPMG LLP
Santa Clara, California
February 17, 2023
45
BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands, except share data)
ASSETS
Current assets:
Cash and cash equivalents
Short-term investments
Restricted investments
Accounts receivable, less allowance for credit losses of $15,029 and $15,142 as of
December 31, 2022 and 2021, respectively
Inventory
Prepaid expenses
Other current assets
Total current assets
Property, plant and equipment:
Land and improvements
Buildings and leasehold improvements
Equipment
Total property, plant and equipment
Less: accumulated depreciation and amortization
Property, plant and equipment, net
Operating lease right-of-use assets
Goodwill, net
Purchased intangibles, net
Other investments
Other assets
Total assets
December 31,
2022
2021
$
$
434,215
1,356,457
5,560
470,783
399,135
5,560
494,645
719,316
124,179
23,604
3,157,976
423,537
572,239
109,136
10,089
1,990,479
27,805
393,620
1,086,595
1,508,020
(1,009,408)
498,612
27,940
385,798
1,099,741
1,513,479
(1,001,840)
511,639
180,952
406,488
332,147
8,830,892
94,599
$ 13,501,666
204,798
347,343
253,939
14,387,006
104,189
$ 17,799,393
The accompanying notes are an integral part of these consolidated financial statements.
46
BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued payroll and employee benefits
Current maturities of long-term debt
Income taxes payable
Other taxes payable
Current operating lease liabilities
Deferred revenue
Other current liabilities
Total current liabilities
Long-term debt, net of current maturities
Deferred income taxes
Operating lease liabilities
Other long-term liabilities
Total liabilities
Commitments and contingent liabilities
Stockholders’ equity:
December 31,
2022
2021
$
$
135,041
194,790
465
11,929
20,499
36,336
52,211
117,437
568,708
1,197,716
1,770,481
153,597
195,912
3,886,414
141,941
276,986
489
10,319
35,980
36,435
50,852
127,936
680,938
10,514
3,064,576
175,938
182,191
4,114,157
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and
outstanding - none
Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares
issued - 25,162,075 and 25,133,530 at 2022 and 2021, respectively; shares
outstanding - 24,521,583 and 24,853,986 at 2022 and 2021, respectively
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares
issued and outstanding - 5,074,130 and 5,078,452 at 2022 and 2021, respectively
Additional paid-in capital
Class A treasury stock at cost, 640,492 shares at 2022 and 279,544 shares at 2021
Retained earnings
Accumulated other comprehensive income (loss)
Total stockholders’ equity
Total liabilities and stockholders’ equity
—
2
—
2
1
447,454
(263,586)
9,898,203
(466,822)
9,615,252
$ 13,501,666
1
441,733
(106,290)
13,525,343
(175,553)
13,685,236
$ 17,799,393
The accompanying notes are an integral part of these consolidated financial statements.
47
BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income (Loss)
(In thousands, except per share data)
Net sales
Cost of goods sold
Gross profit
Selling, general and administrative expense
Research and development expense
Income from operations
Interest expense
Foreign currency exchange (gains) losses, net
(Gains) losses from change in fair market value of equity
securities and loan receivable
Other (income), net
Net income (loss) before income taxes
Benefit from (Provision for) income taxes
Net income (loss)
Basic earnings (loss) per share:
Net income (loss) per basic share
Weighted average common shares - basic
Diluted earnings (loss) per share:
Net income (loss) per diluted share
Weighted average common shares - diluted
Year Ended December 31,
2022
2021
2020
2,802,249 $
1,234,919
1,567,330
827,825
256,889
482,616
38,114
(205)
2,922,545 $
1,284,449
1,638,096
877,122
260,638
500,336
1,551
2,753
2,545,626
1,107,739
1,437,887
798,798
217,763
421,326
21,861
1,771
5,193,554
(44,574)
(4,704,273)
1,076,738
(3,627,535) $
(4,926,248)
(26,775)
5,449,055
(1,194,798)
4,254,257 $
(4,495,825)
(24,488)
4,918,007
(1,103,778)
3,814,229
(121.79) $
29,785
142.61 $
29,831
128.13
29,768
(121.79) $
29,785
140.83 $
30,208
126.47
30,160
$
$
$
$
The accompanying notes are an integral part of these consolidated financial statements.
48
BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
Net income (loss)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale (AFS)
investments
Other comprehensive income (loss), net of tax
Comprehensive income (loss)
Year Ended December 31,
2021
$ (3,627,535) $ 4,254,257 $ 3,814,229
2020
2022
(296,028)
20,859
(469,088)
15,099
371,057
(3,806)
(16,100)
(291,269)
2,553
369,804
$ (3,918,804) $ 3,796,248 $ 4,184,033
(4,020)
(458,009)
The accompanying notes are an integral part of these consolidated financial statements.
49
BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)
Cash flows from operating activities:
Cash received from customers
Cash paid to suppliers and employees
Interest paid, net
Income tax payments, net
Dividend proceeds and miscellaneous receipts, net
Proceeds from (payments for) forward foreign exchange contracts, net
Net cash provided by operating activities
Cash flows from investing activities:
Payments for purchases of property, plant and equipment
Proceeds from dispositions of property, plant and equipment
Proceeds from divestiture of a division
Payments for acquisitions, net of cash received
Recovery of (payments for) purchases of intangible assets
Payments for investment in loan receivable
Payments for purchases of marketable securities and investments
Proceeds from sales of marketable securities and investments
Proceeds from maturities of marketable securities and investments
Net cash used in investing activities
Cash flows from financing activities:
Year Ended December 31,
2021
2022
2020
$ 2,699,401
(2,408,043)
(24,435)
(158,259)
68,184
17,599
194,447
$ 2,886,489
(2,127,939)
(2,251)
(134,683)
35,282
12,566
669,464
$ 2,531,135
(1,877,344)
(21,639)
(65,244)
21,488
(3,424)
584,972
(112,782)
161
1,360
(100,746)
(1,375)
—
(2,060,238)
708,214
357,813
(1,207,593)
(133,746)
52
—
(125,516)
—
(453,440)
(851,627)
425,537
341,359
(797,381)
(108,564)
70
12,240
(96,655)
3,414
—
(248,457)
89,734
278,324
(69,894)
Proceeds from issuance of Notes, net of debt financing costs
Payments on long-term borrowings
1,186,220
(510)
—
(3,020)
—
(426,938)
Proceeds from issuance of common stock and from reissuance of treasury
stock under the employee stock purchase plan and upon exercise of stock
options
Tax payments from net share settlement
Payments for purchases of treasury stock
Payments of contingent consideration
Net cash provided by (used in) financing activities
Effect of foreign exchange rate changes on cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
17,560
(13,967)
(215,679)
(48)
973,576
2,981
(36,589)
471,133
434,544
$
20,632
(22,482)
(49,998)
(561)
(55,429)
(12,636)
(195,982)
667,115
471,133
$
20,198
(12,930)
(100,004)
(3,367)
(523,041)
12,427
4,464
662,651
667,115
$
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated
balance sheets that agrees to the same amounts shown in the consolidated statements of cash flows (in thousands):
Cash and cash equivalents
Restricted cash included in Other current assets
Restricted cash included in Other assets
Total cash, cash equivalents and restricted cash shown in the consolidated
statements of cash flows
Year Ended December 31,
$
2022
434,215
13
316
$
2021
470,783
14
336
$
2020
662,205
3,994
916
$
434,544
$
471,133
$
667,115
These restricted cash items are primarily related to performance guarantees and other restricted deposits.
The accompanying notes are an integral part of these consolidated financial statements.
50
BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
Common
Stock
Additional Paid-
in Capital
Treasury Stock
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Stockholders'
Equity
$
Balance at December 31, 2019
Net income
Other comprehensive income, net of
tax
Issuance of common stock
Stock compensation expense
Purchase of treasury stock
Reissuance of treasury stock
Balance at December 31, 2020
Net income
Other comprehensive loss, net of tax
Issuance of common stock
Stock compensation expense
Purchase of treasury stock
Reissuance of treasury stock
Balance at December 31, 2021
Net loss
Other comprehensive loss, net of tax
Issuance of common stock
Stock compensation expense
Purchase of treasury stock
Reissuance of treasury stock
3
—
—
—
—
—
—
3
—
—
—
—
—
—
3
—
—
—
—
—
—
$
410,020
—
$
(38,397) $ 5,472,564
— 3,814,229
$
(87,348) $ 5,756,842
— 3,814,229
—
7,268
41,556
—
(29,468)
429,376
—
—
(1,850)
51,160
—
(36,953)
441,733
—
—
(3,373)
60,917
—
(51,823)
—
—
—
(100,004)
38,494
(99,907)
—
—
—
—
(9,034)
9,277,759
— 4,254,257
369,804
—
—
—
0
282,456
369,804
7,268
41,556
(100,004)
(8)
9,889,687
— 4,254,257
—
—
—
(49,998)
—
—
—
—
(458,009)
—
—
—
(458,009)
(1,850)
51,160
(49,998)
43,615
(106,290)
(6,673)
13,525,343
— (3,627,535)
—
—
—
(215,679)
58,383
—
—
395
—
(175,553)
(11)
13,685,236
— (3,627,535)
(291,269)
(3,373)
60,917
(215,679)
6,955
(291,269)
—
—
—
—
Balance at December 31, 2022
$
3
$
447,454
$ (263,586) $ 9,898,203
$ (466,822) $ 9,615,252
The accompanying notes are an integral part of these consolidated financial statements.
51
BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements
1.
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and
majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of
intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally
accepted accounting principles requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Immaterial Correction to Previously Issued Consolidated Financial Statements
During the fourth quarter of 2022, we determined that an error existed in our previously issued consolidated
financial statements. Specifically, we identified certain software development costs that were expensed prior to and
during 2020, 2021 and 2022 which should have been capitalized in accordance with Accounting Standards
Codification 350, Intangibles – Goodwill and Other (“ASC 350”). The error was evaluated under the U.S. Securities
and Exchange Commission's ("SEC's") authoritative guidance on evaluating the materiality of prior period
misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not
quantitatively or qualitatively material to the previously issued annual or interim consolidated financial statements.
Although the error was not material to any period, we revised the accompanying historical consolidated financial
statements for the years ended December 31, 2021 and 2020 to reflect the internal-use software capitalization and
related amortization for comparative purposes.
The effect of the revision to our consolidated balance sheet as of December 31, 2021 was as follows (in millions):
Consolidated Balance Sheet:
Prepaid expenses
Property, plant and equipment, net
Other assets
Deferred income taxes
Retained earnings
As reported
December 31, 2021
Adjustment
As revised
$
107.7 $
491.0
102.7
3,059.1
13,507.2
1.4 $
20.7
1.5
5.5
18.1
109.1
511.7
104.2
3,064.6
13,525.3
The effect of the revision to our consolidated statements of income (loss) and consolidated statements of cash flows
for the years ended December 31, 2021 and 2020 were as follows (in millions, except per share data):
Year Ended December 31, 2021
Adjustment
As reported
As revised
Consolidated Statements of Income (Loss):
Cost of goods sold
Selling, general and administrative expense
Research and development expense
Income from operations
Benefit from (provision for) income taxes
Net income (loss)
Net income (loss) per basic share
Net income (loss) per diluted share
$
1,281.9 $
879.6
271.7
489.4
(1,192.2)
4,245.9
142.33
140.56
2.6 $
(2.5)
(11.1)
10.9
(2.6)
8.4
0.28
0.27
1,284.5
877.1
260.6
500.3
(1,194.8)
4,254.3
142.61
140.83
52
Year Ended December 31, 2021
Adjustment
As reported
As revised
Consolidated Statement of Cash Flows:
Net cash provided by operating activities
Net cash used in investing activities
Consolidated Statements of Income (Loss):
Cost of goods sold
Selling, general and administrative expense
Research and development expense
Income from operations
Benefit from (provision for) income taxes
Net income (loss)
Net income (loss) per basic share
Net income (loss) per diluted share
Consolidated Statement of Cash Flows:
Net cash provided by operating activities
Net cash used in investing activities
$
$
$
656.5 $
(784.4)
13.0 $
(13.0)
669.5
(797.4)
Year Ended December 31, 2020
Adjustment
As reported
As revised
1,107.8 $
800.3
226.6
411.0
(1,101.4)
3,806.3
127.86
126.20
(0.1) $
(1.5)
(8.8)
10.4
(2.4)
8.0
0.27
0.27
1,107.7
798.8
217.8
421.3
(1,103.8)
3,814.2
128.13
126.47
Year Ended December 31, 2020
Adjustment
As reported
As revised
575.3 $
(60.3)
9.6 $
(9.6)
585.0
(69.9)
In addition, the revision effected prior year amounts disclosed in Note 7, Income Taxes; Note 12, Supplemental
Cash Flow Information; Note 15, Segment Information and Note 18 Quarterly Financial Data (Unaudited).
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or
less which are readily convertible into cash.
Short-term Restricted Investments
Short-term restricted investments of $5.6 million at both December 31, 2022 and 2021 represent a money market
fund that is provided as collateral to secure worker's compensation and general liability insurance.
Available-for-Sale Investments
Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities and
U.S. government sponsored agencies. Management classifies investments at the time of purchase and reevaluates
such classification at each balance sheet date. Investments with maturities beyond one year may be classified as
short-term based on their liquid nature and because such marketable securities represent the investment of cash that
is available for current operations. Available-for-sale investments are reported at fair value based on quoted market
prices and other observable market data. Unrealized gains and losses are reported as a component of other
comprehensive income (loss), net of any related tax effect. Realized gains and losses and other-than-temporary
impairments on investments are included in Other (income), net (see Note 11).
53
Concentration of Credit Risk
Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash
equivalents, investments, foreign exchange contracts, trade accounts receivable and loans receivable. Cash and cash
equivalents and investments are placed with various highly rated major financial institutions located in different
geographic regions.
The forward contracts used in managing our foreign currency exposures have an element of risk in that the
counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the
counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of
non-performance by these counterparties, the carrying values of our financial instruments represent the maximum
amount of loss we would have incurred as of our fiscal year-end.
Credit risk for trade accounts receivable is generally limited due to the large number of customers and their
dispersion across many geographic areas. We manage our accounts receivable credit risk through ongoing credit
evaluation of our customers' financial conditions. We generally do not require collateral from our customers.
Loans receivable represent the Loan extended to SHB and is collateralized by the pledge of certain trust interests
under the Sartorius family trust ("Trust"), which upon termination of the Trust represent the right to receive
Sartorius ordinary shares. The collateral is subject to market volatility based on fluctuation in value of the Sartorius
ordinary shares.
Accounts Receivable and Allowance for Credit Losses
We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We
consider receivables past due based on the contractual payment terms. Amounts later determined and specifically
identified to be uncollectible are charged or written off against the allowance for credit losses.
Any adjustments made to our historical loss experience reflect current differences in asset-specific risk
characteristics, including, for example, accounts receivable by customer type (public or government entity versus
private entity) and by geographic location of the customer.
Changes in our allowance for credit losses were as follows (in millions):
December 31,
Beginning balance
Provision for expected credit losses
Write-offs charged against the allowance
Recoveries collected
Ending balance
Inventory
2022
2021
2020
$
$
15.1 $
1.7
(1.9)
0.1
15.0 $
19.8 $
1.4
(6.4)
0.3
15.1 $
20.2
1.2
(1.6)
—
19.8
Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs.
Cost is determined using standard costs, which approximate actual costs, and are relieved from inventory on a first-
in, first-out or average cost basis. We classify our inventories based on our historical and anticipated levels of sales;
any inventory in excess of its normal operating cycle (1 – 3 years depending on our product line) is classified as
long-term on our consolidated balance sheets. The long-term inventory was immaterial as of December 31, 2022
and 2021.
54
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Additions and
improvements are capitalized, and maintenance and repairs are expensed as incurred. Included in property, plant and
equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and
capitalized software, including costs for software developed or obtained for internal use.
Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful
lives of property, plant and equipment are generally as follows: buildings, 10-50 years; leasehold improvements, the
life of the improvements or the term of the lease, whichever is shorter; reagent rental equipment, 1-5 years;
equipment, 3-12 years; and computer software, 3-5 years.
When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are
relieved from the accounts and the net gain or loss is included in operating expenses.
Internal-Use Software Development Costs
Costs incurred in the development of internal use software during the application development stage are capitalized
and included in Property, plant and equipment, net on the consolidated balance sheets. Such capitalized costs
include costs directly associated with the development of the applications. Capitalization of such costs begins when
the preliminary project stage is complete and ceases at the point the project is substantially complete and is ready
for its intended purpose. Internal-use software is amortized on a straight-line basis over the estimated useful life of
between 3-5 years. Costs incurred during the preliminary project stage, as well as maintenance and training costs,
are expensed as incurred.
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use
(“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our consolidated balance sheets.
Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term
debt, net of current maturities in our consolidated balance sheets.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized
at the commencement date based on the present value of lease payments over the lease term. As our leases do not
provide an implicit rate, we use our incremental borrowing rate based on the information available at the
commencement date in determining the present value of lease payments. Operating lease ROU assets also include
any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate
the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and
operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by
the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option
to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option
to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is
recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and
non-lease components.
For our reagent rental contracts, which are classified as operating leases and we act as a lessor, are more fully
described below under the caption "Reagent Rental Agreements."
55
Intangible Assets
Our intangible assets principally include goodwill, acquired technology / know how, license, tradenames, customer
relationships, and in-process research and development. Intangible assets with finite lives, which include acquired
technology / know how, tradenames, licenses and customer relationships, are carried at cost and amortized using the
straight-line method over their estimated useful lives.
The estimated useful lives used in computing amortization of intangible assets are as follows:
Customer relationships/lists
Know how
Developed product technology
Licenses
Tradenames
Covenants not to compete
4 – 16 years
14 years
2 – 20 years
12 – 13 years
6 – 10 years
3 – 10 years
Intangible assets with indefinite lives, which include only goodwill and in-process research and development assets,
are recorded at cost and evaluated at least annually for impairment.
Impairment of Long-Lived Assets
We review long-lived assets, such as property, plant and equipment and finite-lived intangible assets, for
impairment whenever events indicate that the carrying amounts might not be recoverable. Recoverability of
property, plant and equipment, and other finite-lived intangible assets are measured by comparing the projected
undiscounted net cash flows associated with those assets to their carrying values. If an asset is considered impaired,
it is written down to its fair value, which is determined based on the asset's projected discounted cash flows or
appraised value, depending on the nature of the asset. For purposes of recognition of impairment for assets held for
use, we group assets and liabilities at the lowest level for which cash flows are separately identifiable.
There were no impairments of finite-lived intangible assets for the years ended December 31, 2022, 2021 and 2020.
Impairment of Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable
intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually
in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a
business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such
indicators may include deterioration in general economic conditions, negative developments in equity and credit
markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative
effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among
others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the
impairment of goodwill.
We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit
is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative
goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if
we elect to bypass the qualitative assessment, goodwill is tested at the reporting unit level using a quantitative
impairment test.
56
We have two reporting units, which are the operating segments, Life Science and Clinical Diagnostics. We elected
to perform a qualitative assessment of goodwill and determined that it is not more likely than not that the fair values
of our reporting units are less than their carrying amounts and that goodwill is not impaired for any of our reporting
units.
Impairment of Indefinite-Lived Intangible Assets
For indefinite-lived intangible assets such as in-process research and development, we conduct an impairment
analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a
qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process
research and development assets exceeds its fair value. The qualitative assessment requires the consideration of
factors such as adverse macroeconomic conditions, declining market and industry trends in which the company
operates, rising cost factors including inflation, and changes in projected future cash flows. If we determine it is
more likely than not that the fair value is less than its carrying amount of the in-process research and development
assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process
research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment
loss is recognized for the excess. We elected to perform a qualitative assessment of indefinite-lived intangible assets
and determined that it is not more likely than not that the fair value is less than its carrying amount and that in-
process research and development are not impaired.
Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been included in the financial
statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax
credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for
the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred
tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making
such determination, we consider all available positive and negative evidence, including scheduled reversals of
deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations.
When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes
will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position
will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax
benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit
that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits
is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax
law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination,
or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to
unrecognized tax benefits in the provision for income taxes.
Revenue Recognition
We recognize revenue from operations through the sale of products, services, license of intellectual property and
rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised
products or services to customers in an amount that reflects the consideration we expect to receive in exchange for
those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added
tax, etc.), which are subsequently remitted to government authorities.
57
We enter into contracts that can include various combinations of products and services, which are generally
accounted for as distinct performance obligations. A product or service is considered distinct if it is separately
identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service
on its own or with other resources that are readily available to the customer. The transaction consideration is
allocated between separate performance obligations of an arrangement based on the stand-alone selling price
(“SSP”) for each distinct product or service.
We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by
transferring control of the product to the customer. We use judgment to evaluate whether and when control has
transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and
customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For
products that include installation, the product and installation are separate performance obligations. The product
revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service
revenue is recognized when the product installation is completed.
Prior to the fourth quarter of 2022, revenue associated with equipment that required installation service was not
recognized until customer acceptance was obtained which was after installation was completed. During the fourth
quarter of 2022, we reassessed our customer acceptance criteria and determined that revenue associated with
equipment that required installation should have been recognized upon delivery, prior to installation and customer
acceptance. We evaluated the error and concluded that it was not material to the previously issued annual or interim
consolidated financial statements.
At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered
variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the
estimated amount of product returns.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a
stand-ready performance obligation. For arrangements that include a combination of products and services, the
transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used
to determine the stand-alone selling prices for product and service revenues is based on the observable prices when
the product or services have been sold separately.
We recognize revenues for a functional license of intellectual property at a point in time when the control of the
license and technology transfers to the customer. For license agreements that include sales or usage-based royalty
payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the
performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially
satisfied.
The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of
purchasing our products and services, not to either provide or receive financing to or from our customers. We
record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length
of one year or less. Our payment terms vary by the type and location of our customer, and the products and services
offered. The term between invoicing and when payment is due is not significant.
Reagent Rental Agreements
Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on
a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as
well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract
commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease
classification as operating or sales-type lease. The lease term used in performing the lease classification test,
includes the noncancellable period of the lease together with those periods covered by lease extension options if the
customer is reasonably certain to exercise that option, the periods covered by lease termination options if the
58
customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not
terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term
for reagent rental agreements, including the impact from any associated contractual termination penalties, are
subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee
to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term
has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee
to purchase the underlying asset.
We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not
governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC
842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements
based on relative standalone selling prices. The determination of the transaction price requires judgment and
consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have
allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to
such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.
Maintenance services, along with the reagents, are allocated to the non-lease elements and recognized as income
over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents
revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables
are consumed by the customer.
Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending
on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease
payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type
leases have historically been immaterial and we do not enter into direct finance leases. Our reported lease income is
primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer.
Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total
revenue in 2022, 2% of total revenue in 2021 and 3% of total revenue in 2020. Such revenue forms part of the Net
sales in our consolidated statements of income (loss).
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have
been one year or less. These costs include our internal sales force and certain partner sales incentive programs and
are recorded within Selling, general and administrative expense in our consolidated statements of income.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product
or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are
presented in our Segment Information footnote (see Note 15).
Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements
including installation services. The deferred revenue balance at December 31, 2022 and December 31, 2021 was
$71.9 million and $71.0 million, respectively. The short-term deferred revenue balance at December 31, 2022 and
December 31, 2021 was $52.2 million and $50.9 million, respectively.
We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one
year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience,
specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our
consolidated statements of income.
59
Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the consolidated
balance sheets. Change in our warranty liability were as follows (in millions):
January 1
Provision for warranty
Actual warranty costs
December 31
Shipping and Handling
2022
2021
2020
$
$
12.7 $
8.8
(10.9)
10.6 $
9.8
14.8
(11.9)
12.7
$
$
9.0
9.4
(8.6)
9.8
We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of
control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.
Research and Development
All research and development costs are expensed as incurred. Types of expense incurred in research and
development include materials and supplies, employee compensation, consulting and third-party services,
depreciation, facility costs and information technology.
Foreign Currency
Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each
accounting period. Income statement items are translated at average exchange rates for the period. The resulting
translation adjustments are recorded as a separate component of stockholders’ equity.
Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the consolidated
statements of income. Transaction gains and losses result primarily from fluctuations in exchange rates when
intercompany receivables and payables are denominated in currencies other than the functional currency of our
subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts
As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward
foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect
foreign currency denominated intercompany receivables and payables. We do not use derivative financial
instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts.
As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies
of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date.
The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which
are recorded in Foreign exchange losses, net in the consolidated statements of income. We classify the proceeds
from (payments for) forward foreign exchange contracts as cash flows from operating activities in our consolidated
statements of cash flows.
Share-Based Compensation Plans
Share-based compensation expense for all share-based payment awards granted is determined based on the grant-
date fair value. We recognize these compensation costs over the requisite service period of the award, which is
generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans
are described more fully in Note 10.
60
Earnings (Loss) Per Share
We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class
B) using the two-class method required for participating securities. Our participating securities include Class A and
Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate
equally in dividend distributions. No dividends were distributed or declared during any of the periods presented.
Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based
on the weighted average number of the respective class of common stock outstanding for the year.
Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by
the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into
account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses
the average share price for the period in determining the number of potential common shares that are to be added to
the weighted average number of shares outstanding. Potential common shares are excluded from the diluted
earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.
The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per
share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as
follows (in thousands):
Basic weighted average shares common outstanding
Effect of potentially dilutive stock options, restricted
stock and performance stock awards
Diluted weighted average common shares outstanding
Anti-dilutive shares
Fair Value of Financial Instruments
Year Ended December 31,
2021
2022
2020
29,785
29,831
29,768
—
29,785
325
377
30,208
33
392
30,160
44
For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable,
marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts
approximate fair value.
The estimated fair value of financial instruments is based on the exchange price that would be received for an asset
or paid to transfer a liability (an exit price) using available market information or other appropriate valuation
methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a
current market exchange as considerable judgment is required in interpreting market data used to develop estimates
of fair value. The use of different market assumptions or estimation techniques could have a material effect on the
estimated fair value (see Note 3).
61
Variable Interest Entities
We enter into relationships with or make investments in other entities that may be variable interest entities ("VIE").
A VIE is consolidated in the financial statements if we are the primary beneficiary. The primary beneficiary has the
power to direct activities that most significantly impact the economic performance of the VIE and has the obligation
to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.
In 2021, we extended a loan to a VIE, Sartorius-Herbst Beteiligungen II GmbH ("SHB"), a private limited company
incorporated under the laws of Germany (See Note 3). We have not consolidated this entity because we do not have
the power to direct the activities that most significantly impact the VIE’s economic performance related to
repayment of the loan or cash management of the SHB and, thus, we are not considered the primary beneficiary of
the VIE. We believe that our maximum exposure to loss as a result of our involvement with the VIE is limited to the
receivable due to us from the VIE under the terms of the loan.
Equity Investments
Investments in publicly traded companies in which we do not have the ability to exercise significant influence are
reported at fair value, with unrealized gains and losses reported as a component of change in (gains) losses from
change in fair market value of equity securities and loan receivable in our consolidated statements of income.
Companies in which we do not have a controlling financial interest, but over which we have significant influence,
are accounted for using the equity method. Our share of the after-tax earnings of equity method investees is
included in Other (income), net in our consolidated statements of income. Investments in privately held companies
in which we do not have the ability to exercise significant influence are accounted for using the cost method with
adjustments for observable changes in price or impairments (see Note 3). We monitor our relationships with
investees when changes occur that could affect whether we have the ability to exercise significant influence.
Recent Accounting Pronouncements Adopted
In November 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)
No. 2021-10, "Government Assistance." The ASU includes tax credits but not within Topic 740, "Income Taxes,"
cash grants, grants of other assets and project grants. The ASU excludes transactions in which a government is a
customer within Topic 606, "Revenue from Contracts with Customers." The ASU was effective for fiscal years
beginning after December 15, 2021. The adoption of ASU 2021-10 did not have a material impact on our
consolidated financial statements.
In October 2021, the FASB issued ASU 2021-08, "Accounting for Contract Assets and Contract Liabilities from
Contracts with Customers." ASU 2021-08 requires an acquirer in a business combination to recognize and measure
contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition
guidance in Topic 606. Under this approach, the acquirer applies the revenue model as if it had originated the
contracts. This is a departure from the current requirement to measure contract assets and contract liabilities at fair
value. ASU 2021-08 is applied to business combinations occurring on or after January 1, 2023. We early adopted
ASU 2021-08 on January 1, 2022, which did not have a material impact on our consolidated financial statements.
62
In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions.” ASU 2022-03 clarifies the guidance in Topic 820, "Fair Value Measurement," and uses two
examples to differentiate between (1) a restriction that is a characteristic of the security (for which the effect of the
restriction is included in the equity security’s fair value because it is a security-specific characteristic) and (2) a
contractual sale restriction (for which the effect of the restriction is not included in the equity security’s fair value
because it is an entity-specific characteristic). In addition, the amendments clarify that an entity cannot recognize a
contractual sale restriction as a separate unit of account (i.e. as a contra-asset or separate liability); and require new
disclosures for all entities with equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for
fiscal years beginning after December 15, 2023, and early adoption is permitted for both interim and annual
financial statements. We early adopted ASU 2022-03 during the third quarter of 2022, which did not have a material
impact on our consolidated financial statements.
2.
ACQUISITIONS
Curiosity Diagnostics Acquisition:
On August 3, 2022 (the "Acquisition Date"), we acquired all equity interests of Curiosity Diagnostics, sp.z o.o.
("Curiosity") for a total consideration of $137.1 million, including the estimated fair value of contingent
consideration. The contingent consideration of up to $70.0 million is payable upon achievement of certain
technological development and sales-related milestones.
Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-
answer, rapid diagnostics PCR system for the molecular diagnostics market. The strategic rationale for the
transaction was to facilitate our entry into the molecular disease testing market with a differentiated platform. We
believe this acquisition will complement our Clinical Diagnostics product offerings. The acquisition was included in
our Clinical Diagnostics segment's results of operations from the Acquisition Date. The amount of acquisition-
related costs was not material.
The acquisition of Curiosity was accounted for as a business combination.
The fair value of consideration transferred for the Curiosity acquisition consists of the following (in millions):
Purchase price (cash)
Fair value of contingent consideration (earn-out)
Fair value of total consideration transferred
$
$
101.0
36.1
137.1
63
The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the
Acquisition Date (in millions):
In-process research and development
Deferred tax liabilities
Other identifiable assets acquired, net
Net identifiable assets acquired
Goodwill
Net assets acquired
Preliminary Fair Value
99.0
(18.8)
1.0
81.2
55.9
137.1
$
$
Goodwill related to the acquisition is primarily attributable to opportunities to further develop and enhance the rapid
diagnostics PCR systems and combining the operations and technologies of Bio-Rad and Curiosity, and is not
deductible for tax purposes. In-process research and development (IPR&D) is accounted for as an indefinite-lived
asset. Once the project is completed, the carrying value of the IPR&D will be amortized over the estimated useful
life of the asset. IPR&D is assessed for impairment on an annual basis until the project is completed.
As additional information becomes available, such as finalization of the estimated fair value of the assets acquired
and liabilities assumed that may affect the total consideration transferred, we may revise the preliminary estimates
of fair values of the tangible and intangible assets acquired and liabilities assumed during the remainder of the
measurement period (which will not exceed 12 months from the Acquisition Date). Any such revisions or changes
may be material as we finalize the fair values of the assets acquired and liabilities assumed, including the related tax
effects.
We included Curiosity's estimated fair value of assets acquired and liabilities assumed in our consolidated balance
sheets beginning on the Acquisition Date. The results of operations for Curiosity subsequent to the Acquisition Date
have been included in, but are immaterial to, our consolidated statements of income (loss) for the year ended
December 31, 2022. Pro forma results of operations for the Curiosity acquisition have not been presented because
they are not material to the consolidated statements of income (loss).
Dropworks Acquisition:
On October 15, 2021 (the "Acquisition Date"), we acquired all equity interests of Dropworks, Inc. ("Dropworks")
for a total consideration of $125.5 million.
Dropworks is a development stage company focused on developing a digital PCR product. The strategic rationale
for the transaction was to address additional opportunities in the PCR market. We believe this acquisition will
complement our Life Science product offerings. The acquisition was included in our Life Science segment's results
of operations from the Acquisition Date. The amount of acquisition-related costs was not material.
The acquisition of Dropworks was accounted for as a business combination.
64
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition
Date (in millions):
Intangible assets
Deferred tax assets
Deferred tax liabilities
Other identifiable assets acquired, net
Net identifiable assets acquired
Goodwill
Net assets acquired
$
$
Fair Value
83.6
5.6
(19.5)
0.4
70.1
55.4
125.5
Goodwill related to the acquisition is primarily attributable to the opportunities in the digital PCR market from
combining the know-how and technologies of Bio-Rad and Dropworks, and is not deductible for tax purposes.
The following table summarizes the final fair values and estimated useful life of the components of identifiable
intangible assets acquired as of the Acquisition Date (in millions):
In-process research and development
Covenants not to compete
Total identifiable intangible assets acquired
$
$
81.7
1.9
83.6
4.7
Fair Value
Estimated Useful Life (years)
The acquired covenants not to compete are being amortized over its estimated useful life using the straight-line
method of amortization, which is the term based on the legal rights associated with the covenants not to compete
asset. Amortization of the acquired covenants not to compete of $0.4 million and $0.1 million for the years ended
December 31, 2022 and December 31, 2021, respectively, are included in Selling, general and administrative
expense in the consolidated statements of income (loss).
In-process research and development (IPR&D) is accounted for as an indefinite-lived asset. Once the project is
completed, the carrying value of the IPR&D will be amortized over the estimated useful life of the asset. IPR&D is
assessed for impairment on an annual basis until the project is completed.
We included Dropworks' estimated fair value of assets acquired and liabilities assumed in our consolidated balance
sheets beginning on the Acquisition Date. The results of operations for Dropworks subsequent to the Acquisition
Date have been included in, but are immaterial to, our consolidated statements of income (loss) for the years ended
December 31, 2022 and December 31, 2021. Pro forma results of operations for the Dropworks acquisition have not
been presented because they are not material to the consolidated statements of income (loss).
3.
FAIR VALUE MEASUREMENTS AND INVESTMENTS
We determine the fair value of an asset or liability based on the assumptions that market participants would use in
pricing the asset or liability in an orderly transaction between market participants at the measurement date. The
identification of market participant assumptions provides a basis for determining what inputs are to be used for
pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value
measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes
the inputs into three broad levels as follows:
65
•
•
•
Level 1: Quoted prices in active markets for identical instruments
Level 2: Other significant observable inputs (including quoted prices in active markets for similar
instruments)
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain
investments)
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are
classified in the hierarchy as follows (in millions):
Level 1
Level 2
Level 3
Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper
Time deposits
Asset-backed securities
U.S. government sponsored agencies
Money market funds
Total cash equivalents (a)
Restricted investments (b)
Equity Securities (c)
Loan under the fair value option (d)
Available-for-sale investments:
Corporate debt securities
U.S. government sponsored agencies
Foreign government obligations
Municipal obligations
Asset-backed securities
Total available-for-sale investments (e)
Forward foreign exchange contracts (f)
Total financial assets carried at fair value
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)
Contingent consideration (h)
Total financial liabilities carried at fair value
$
$
$
$
— $
5.7
—
—
31.5
37.2
6.8
8,530.4
—
—
—
—
—
—
—
—
8,574.4 $
21.1 $
—
1.4
6.0
—
28.5
—
—
—
699.3
230.7
13.5
23.1
333.4
1,300.0
1.5
1,330.0 $
— $
—
—
—
—
—
—
—
322.6
21.1
5.7
1.4
6.0
31.5
65.7
6.8
8,530.4
322.6
—
—
—
—
—
—
—
699.3
230.7
13.5
23.1
333.4
1,300.0
1.5
322.6 $ 10,227.0
— $
—
— $
6.2 $
—
6.2 $
— $
35.6
35.6 $
6.2
35.6
41.8
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2021 are
classified in the hierarchy as follows (in millions):
66
Financial assets carried at fair value:
Cash equivalents:
Commercial paper
Time deposits
Asset-backed securities
Foreign government obligations
Municipals obligations
U.S. government sponsored agencies
Money market funds
Total cash equivalents (a)
Restricted investments (b)
Equity securities (c)
Loan under the fair value option (d)
Available-for-sale investments:
Corporate debt securities
U.S. government sponsored agencies
Foreign government obligations
Other foreign obligations
Municipal obligations
Asset-backed securities
Total available-for-sale investments (e)
Forward foreign exchange contracts (f)
Total financial assets carried at fair value
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)
Total financial liabilities carried at fair value
Level 1
Level 2
Level 3
Total
$
— $
7.2
—
—
—
— $
50.7
57.9
6.9
13,977.5
—
—
—
—
—
—
—
—
—
$ 14,042.3 $
39.8 $
10.1
0.1
0.8
0.3
33.6
—
84.7
—
—
—
182.3
44.3
1.0
3.8
9.0
87.3
327.7
1.7
414.1 $
— $
—
—
—
—
—
—
—
—
—
443.1
39.8
17.3
0.1
0.8
0.3
33.6
50.7
142.6
6.9
13,977.5
443.1
—
—
—
182.3
44.3
1.0
3.8
9.0
87.3
327.7
1.7
443.1 $ 14,899.5
—
—
—
—
—
$
$
— $
— $
2.8 $
2.8 $
— $
— $
2.8
2.8
(a) Cash equivalents are included in Cash and cash equivalents in the consolidated balance sheets.
(b) Restricted investments are included in the following accounts in the consolidated balance sheets (in
millions):
Restricted investments
Other investments
Total
December 31,
2022
December 31,
2021
$
$
5.6
1.2
6.8
$
$
5.6
1.3
6.9
(c) Equity securities are included in the following accounts in the consolidated balance sheets (in millions):
Short-term investments
Other investments
Total
December 31,
2022
December 31,
2021
$
$
56.5
8,473.9
8,530.4
$
$
71.4
13,906.1
13,977.5
67
(d) The Loan under the fair value option is included in Other investments in the consolidated balance sheets.
(e) Available-for-sale investments are included in Short-term investments in the consolidated balance sheets.
(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the
consolidated balance sheets.
(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the
consolidated balance sheets.
(h) Contingent considerations in a liability position are included in Other long-term liabilities in the
consolidated balance sheets.
Level 1 Fair Value Measurements
As of December 31, 2022, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius
AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical,
chemical and food and beverage industries. We did not purchase any incremental shares for the years ended
December 31, 2022 and 2021. We own approximately 37% of the outstanding ordinary shares (excluding treasury
shares) and 28% of the preference shares of Sartorius as of December 31, 2022. The Sartorius family trust (Sartorius
family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of
Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of
Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have
tried and failed to obtain access to operating or financial information necessary to apply the equity method of
accounting.
The change in fair market value on our investment in Sartorius for the twelve months ended December 31, 2022 was
$5.07 billion loss and is recorded in our consolidated statements of income (loss).
Level 2 Fair Value Measurements
To estimate the fair value of Level 2 debt securities as of December 31, 2022 and 2021, our primary pricing
provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing
sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will
utilize our custodian supplied pricing as the secondary pricing source.
Available-for-sale investments consist of the following (in millions):
Short-term investments:
Corporate debt securities
Municipal obligations
Asset-backed securities
U.S. government sponsored agencies
Foreign government obligations
December 31, 2022
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Allowances
for Credit
Losses
Estimated
Fair
Value
$
$
709.9 $
23.4
339.6
233.9
13.8
1,320.6 $
0.2 $
—
0.1
—
—
0.3 $
(10.8)
(0.3)
(6.3)
(3.2)
(0.3)
(20.9) $
— $
—
—
—
—
— $
699.3
23.1
333.4
230.7
13.5
1,300.0
68
The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31,
2022 by contractual maturity date (in millions):
Mature in less than one year
Mature in one to five years
Mature in more than five years
Total
Available-for-sale investments consist of the following (in millions):
Amortized
Cost
Estimated Fair
Value
$
$
323.9 $
834.9
161.8
1,320.6 $
321.4
820.8
157.8
1,300.0
Short-term investments:
Corporate debt securities
Municipal obligations
Asset-backed securities
U.S. government sponsored agencies
Foreign government obligations
Other foreign obligations
Total
December 31, 2021
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Estimated
Fair
Value
$
$
181.9 $
9.0
87.5
44.3
1.0
3.8
327.5 $
0.5 $
—
0.1
—
—
—
0.6 $
(0.2) $
—
(0.2)
—
—
—
(0.4) $
182.2
9.0
87.4
44.3
1.0
3.8
327.7
As of December 31, 2022 there were no significant continuous unrealized losses greater than 12 months.
Our evaluation of credit losses for available-for-sale debt securities included the extent to which the fair value is
less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or
geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are
limited to the amount that the fair value of an instrument is less than its amortized cost basis.
At December 31, 2022, we have concluded that all payments related to our available-for-sale investments are
expected to be made in full and on time at par value. The diminution of value in the intervening period is due to
market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns
surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments
portfolio as of December 31, 2022.
Included in Other current assets are $11.6 million and $2.2 million of interest receivable as of December 31, 2022
and December 31, 2021, respectively, primarily associated with securities in our available-for-sale investments
portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature
of our interest receivable asset, we have made an accounting policy election not to measure an allowance for
credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue
greater than one year to be impaired for purposes of write-off. For the year ended December 31, 2022, write-offs
of uncollected interest receivable were not material.
69
As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward
foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that
affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial
instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As
a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each
balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of December 31,
2022 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was
derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting
gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the
related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the
consolidated statements of income (loss).
The following is a summary of our forward foreign currency exchange contracts (in millions):
Contracts maturing in January through March 2023 to sell foreign currency:
Notional value
Unrealized gain/(loss)
Contracts maturing in January through March 2023 to purchase foreign currency:
Notional value
Unrealized gain/(loss)
December 31,
2022
$
$
$
$
723.4
(3.7)
128.9
(1.0)
Included in Other investments in the consolidated balance sheet are investments without readily determinable fair
value measured at cost with adjustments for observable price changes or impairments. The carrying value of these
investments was $6.5 million as of December 31, 2022 and 2021.
Also included in Other investments in the consolidated balance sheet are our equity method investments, for which
our share of the equity method investees earnings is included in Other (income), net in our consolidated statements
of income (loss). The carrying value of these investments, net of impairments, was $26.7 million and $29.9 million
as of December 31, 2022 and December 31, 2021, respectively.
Level 3 Fair Value Investments
During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh
("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of
€400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity
(“Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family
trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust
interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares.
Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at
maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the
acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares,
that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for
accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is
estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which
results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value
of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used
to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in
years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may
materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a
decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the
Loan and value appreciation right, including accrued interest are recognized in (gains) losses from change in fair
70
value of equity securities and loan receivable in our consolidated statements of income (loss). The overall change in
fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan
receivable during the twelve months ended December 31, 2022 was $100.6 million, which includes $25.6 million
for the change in fair market value for the Loan and $75.0 million for the change in fair market value of the value
appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the
value of the Sartorius ordinary shares. As of December 31, 2022, the €400.0 million principal amount of the loan is
still due on January 31, 2029.
The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):
December 31, 2021
Net decrease in estimated fair market value of the loan
included in Gains (losses) in fair market value of equity
securities and loan receivable
Foreign currency adjustments gains (losses), net
December 31, 2022
$
$
443.1
(100.6)
(19.9)
322.6
During the third quarter of 2022, we recognized a contingent consideration liability upon our acquisition of
Curiosity which represents future potential payments of up to $70.0 million payable in cash upon the achievement
of certain technological development and revenue milestones, commencing on the Acquisition Date through
June 30, 2027. At the Acquisition Date, the fair value of the contingent consideration of $36.1 million was
determined by using a probability-weighted income approach related to the achievement of the technological
development and revenue milestones. The significant assumptions used to estimate the fair value of the contingent
consideration include an estimate of the probability of achievement and the discount rate. The probability of
achievement is subject to estimation uncertainty and actual amounts realized may materially differ. An increase in
the expected probability of achievement may result in a higher fair value, whereas a decrease in expected
probability of achievement may result in a lower fair value. The fair value of the contingent consideration is
remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The
contingent consideration was recorded at its estimated fair value of $35.6 million as of December 31, 2022.
The following table provides a reconciliation of the Level 3 Curiosity contingent consideration liability measured at
estimated fair value (in millions):
January 1, 2022
Acquisitions with contingent consideration
Decrease in estimated fair value of contingent
consideration included in Selling, general, and
administrative expense
December 31, 2022
$
$
—
36.1
(0.5)
35.6
The following table provides quantitative information about Level 3 inputs for fair value measurement of our
Curiosity contingent consideration liability as of December 31, 2022. Significant increases or decreases in these
inputs in isolation could result in a significantly lower or higher fair value measurement.
Curiosity Diagnostic Probability-weighted income approach Discount rate
5.4 %
Valuation Technique
Unobservable Input Percentage
71
4.
GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS
Changes to goodwill by segment were as follows (in millions):
Balances as of January 1:
Goodwill
2022
2021
Life
Science
Clinical
Diagnostics
Total
Life
Science
Clinical
Diagnostics
Total
$
333.3
$
349.2
$ 682.5
$
277.9
$
349.2
$ 627.1
Accumulated impairment losses and write-offs
Goodwill, net
(41.8)
291.5
(293.4)
(335.2)
55.8
347.3
(41.8)
236.1
(293.4)
(335.2)
55.8
291.9
Acquisitions (see Note 2)
Foreign currency adjustments
Period increase, net
Balances as of December 31:
Goodwill
Accumulated impairment losses and write-offs
—
—
—
55.9
3.3
59.2
55.9
3.3
59.2
55.4
—
55.4
—
—
—
55.4
—
55.4
333.3
(41.8)
408.4
741.7
(293.4)
(335.2)
333.3
(41.8)
349.2
682.5
(293.4)
(335.2)
Goodwill, net
$
291.5
$
115.0
$ 406.5
$
291.5
$
55.8
$ 347.3
Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in
millions):
Customer relationships/lists
Know how
Developed product technology
Licenses
Tradenames
Covenants not to compete
Total finite-lived intangible assets
In-process research and development
Total purchased intangible assets
Weighted-
Average
Amortization
Period (years)
5.02
2.75
12.83
5.84
6.56
3.13
December 31, 2022
Purchase
Price
Accumulated
Amortization
Net
Carrying
Amount
$
$
104.7 $
166.2
211.1
59.0
6.1
6.4
553.5
191.0
744.5 $
(89.9) $
(153.9)
(121.6)
(38.5)
(4.5)
(4.0)
(412.4)
—
(412.4) $
14.8
12.3
89.5
20.5
1.6
2.4
141.1
191.0
332.1
72
Customer relationships/lists
Know how
Developed product technology
Licenses
Tradenames
Covenants not to compete
Total finite-lived intangible assets
In-process research and development
Total purchased intangible assets
Weighted-
Average
Amortization
Period (years)
5.27
3.75
13.42
6.79
7.33
3.78
December 31, 2021
Purchase
Price
Accumulated
Amortization
Net
Carrying
Amount
$
$
111.8 $
171.6
215.6
64.9
6.3
6.5
576.7
86.3
663.0 $
(90.7) $
(154.9)
(115.6)
(40.6)
(4.4)
(2.9)
(409.1)
—
(409.1) $
21.1
16.7
100.0
24.3
1.9
3.6
167.6
86.3
253.9
Amortization expense related to purchased intangible assets for the years ended December 31, 2022, 2021 and 2020
was $24.9 million, $28.4 million and $27.5 million, respectively. Estimated future amortization expense (based on
existing purchased finite-lived intangible assets) for the years ending December 31, 2023, 2024, 2025, 2026, 2027
and thereafter is $23.5 million, $20.7 million, $18.8 million, $13.8 million, $11.5 million, and $52.8 million,
respectively.
No impairment losses related to goodwill and purchased intangibles were recorded in 2022 and 2021.
5.
INVENTORY
Following are the components of Inventory at December 31, 2022 and December 31, 2021 (in millions):
Inventory:
Raw materials
Work in process
Finished goods
Total Inventory
December 31,
2022
December 31,
2021
228.8
220.9
269.6
719.3
$
116.9
198.0
257.3
572.2
$
6.
NOTES PAYABLE AND LONG-TERM DEBT
The principal components of long-term debt are as follows (in millions):
3.3%, Senior Notes due 2027
3.7%, Senior Notes due 2032
Less unamortized discounts and debt issuance costs
Long-term debt less unamortized discounts and debt issuance costs
Finance leases and other debt
Less current maturities
Long-term debt
December 31,
2022
December 31,
2021
$
400.0 $
800.0
(12.4)
1,187.6
10.6
(0.5)
$
1,197.7 $
—
—
—
—
11.0
(0.5)
10.5
73
Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had
$207.5 million available for borrowing and usage as of December 31, 2022, which was reduced by $4.3 million that
was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.
Senior Notes due 2027 and 2032
In March 2022, pursuant to an indenture we issued $400.0 million in principal amount of Senior Notes due March
2027 (the “2027 Notes”) and $800.0 million in principal amount of Senior Notes due March 2032 (the “2032 Notes”
and, together with the 2027 Notes, the “Notes”). The issuance of the 2027 Notes yielded net cash proceeds of
$395.7 million at an effective rate of 3.5346% and the issuance of the 2032 Notes yielded net cash proceeds of
$790.5 at an effective rate of 3.8429%. The 2027 Notes and the 2032 Notes pay a fixed rate of interest of 3.3% and
3.7% per annum, respectively. Interest on the Notes is payable semi-annually in arrears on March 15 and September
15 of each year until the principal is paid or made available for payment. We have the option to redeem the Notes at
any time, in whole or in part, at a redemption price calculated in accordance with the indenture, plus accrued and
unpaid interest thereon to the redemption date. In the event of a change of control, the holders may require us to
repurchase for cash all or a portion of their notes at a purchase price equal to 101% of the principal amount of the
notes, plus accrued and unpaid interest, if any. Our obligations under the Notes are unsecured senior obligations that
rank equally in right of payment with all of our other existing and future unsecured, unsubordinated debt. The Notes
include covenants that limit our ability to, among other things, (i) grant specified liens, (ii) engage in specified sale
and leaseback transactions, (iii) consolidate or merge with or into other companies or (iv) sell all or substantially all
of our assets. We were in compliance with these covenants as of December 31, 2022.
Credit Agreement
In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement").
Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions,
for working capital and for other general corporate purposes. In November 2021 and April 2022, Bio-Rad entered
into Amendments No. 1 and 2 (“Amendment”) to the Credit Agreement to add LIBOR replacement language,
expand the definition of EBITDA, increase certain financial baskets and to clarify the definitions of certain terms
related to cash in the Leverage Ratio calculation. We had no outstanding borrowings under the Credit Agreement as
of December 31, 2022; however, $0.2 million was utilized for domestic standby letters of credit that reduced our
borrowing availability as of December 31, 2022. The Credit Agreement matures in April 2024. If we had borrowed
against our Credit Agreement, the borrowing rate would have been 6.020% at December 31, 2022, which is based
on the 3-month LIBOR.
The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things.
These ratios and covenants include a leverage ratio test and an interest coverage test, as well as certain restrictions
on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or
consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and
covenants as of December 31, 2022 and 2021.
Maturities of finance leases and other debt at December 31, 2022 were as follows (in millions):
2023
2024
2025
2026
2027
2028 and thereafter
Total Maturities of finance leases and other debt
$
$
0.5
0.5
0.5
0.5
400.4
808.2
1,210.6
74
7.
INCOME TAXES
The following information for the year ended and as at December 31, 2021 and 2020 have been revised to correct
for immaterial errors in prior periods as described in Note 1, “Immaterial Correction to Previously Issued Financial
Statements.”
The U.S. and international components of income before taxes are as follows (in millions):
U.S.
International
Income (loss) before taxes
Year Ended December 31,
2022
(2,403.4) $
(2,300.9)
(4,704.3) $
$
$
2021
2020
2,941.8 $
2,507.3
5,449.1 $
2,350.1
2,567.9
4,918.0
The (benefit from) provision for income taxes consists of the following (in millions):
Current tax expense:
U.S. Federal
State
International
Current tax expense
Deferred tax (benefit) expense:
U.S. Federal
State
International
Deferred tax expense
Non-current tax expense (benefit)
(Benefit from) provision for income taxes
Year Ended December 31,
2021
2022
2020
$
$
112.8 $
20.1
24.1
157.0
(1,121.3)
(83.6)
(36.7)
(1,241.6)
7.9
(1,076.7) $
72.4 $
9.2
32.6
114.2
983.5
69.3
32.1
1,084.9
(4.3)
1,194.8 $
69.9
12.0
22.3
104.2
895.6
54.3
31.5
981.4
18.2
1,103.8
The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:
U. S. statutory tax rate
Impact of foreign operations
U.S. taxation of foreign income
State taxes
Other
Provision (benefit) for income taxes
Year Ended December 31,
2021
2020
2022
21.0 %
(10.0)
10.5
1.1
0.3
22.9 %
21.0 %
(8.6)
8.9
1.3
(0.7)
21.9 %
21.0 %
(9.8)
10.1
1.1
—
22.4 %
75
On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad
and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation
tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax
rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax
assets and liabilities. The Tax Act also amended Internal Revenue Code Section 174 requiring capitalization of
research and experimentation expenditures. The capitalized expenses are amortized over a period of 5 or 15 years.
On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an
Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. Based on
our initial evaluation, we do not believe the Inflation Reduction Act will have a material impact on our income tax
provision and cash taxes. We continue to monitor the changes in tax laws and regulations to evaluate their
potential impact on our business.
Our effective income tax rates were 22.9%, 21.9% and 22.4% for the years ended December 31, 2022, 2021 and
2020, respectively. The effective tax rates for the years ended December 31, 2022, 2021 and 2020 were primarily
driven by the unrealized gain/loss in equity securities that was taxed at 22.5%, 22.4% and 22.1%, respectively, as
well as the geographic mix of earnings.
Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%.
Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the
jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits
and settlements, and generation of tax credits.
Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. Significant components of deferred tax assets and liabilities are as follows (in millions):
Deferred tax assets:
Bad debt, inventory and warranty accruals
Other post-employment benefits, vacation and other reserves
Tax credit and net operating loss carryforwards
Lease obligations
Other
Total gross deferred tax assets
Valuation allowance
Total deferred tax assets
Deferred tax liabilities:
Property and equipment
Lease assets
Investments and intangible assets
Total deferred tax liabilities
Net deferred tax liabilities
December 31,
2022
2021
30.8 $
15.7
128.2
40.8
53.2
268.7
(72.8)
195.9
32.0
23.8
104.5
46.6
65.0
271.9
(46.4)
225.5
39.5
38.7
1,842.8
1,921.0
(1,725.1) $
40.7
44.5
3,155.7
3,240.9
(3,015.4)
$
$
76
The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the
appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and
establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will
not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative
evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not
that certain of our state and foreign deferred tax assets will not be realized as of December 31, 2022, and have
maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax
assets in certain states and foreign jurisdictions increased by $26.4 million for the year ended December 31, 2022.
The valuation allowance for deferred tax assets is as follows (in millions):
Beginning balance
Additions charged to expenses
Deductions from reserves
Ending balance
2022
46.4
26.4
—
72.8
$
$
December 31,
2021
$
$
44.6
1.8
—
46.4
2020
67.2
—
(22.6)
44.6
$
$
As of December 31, 2022, our federal, state and foreign net operating loss carryforwards were approximately
$30.3 million, $83.4 million and $345.6 million, respectively. Of our foreign net operating losses, $127.3 million
may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will
begin to expire in 2023. Our federal and state net operating loss carryforwards, if not utilized, will begin to expire in
2028. As of December 31, 2022, our federal and state tax credit carryforwards were approximately $6.7 million and
$70.7 million, respectively. Our federal tax credits, if not utilized, will begin to expire in 2029, and our state tax
credits, generally, may be carried forward indefinitely.
Federal and state tax laws impose restrictions on the utilization of net operating loss and certain tax credit
carryforwards in the event of a change in our ownership as defined by the Internal Revenue Code Sections 382 and
383. Under Section 382 and 383 of the Internal Revenue Code, substantial changes in our ownership and the
ownership of acquired companies may limit the amount of net operating loss and research and development credit
carryforwards that are available to offset taxable income. The annual limitation would not automatically result in the
loss of net operating loss or research and development credit carryforwards but may limit the amount available in
any given future period.
Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under
examination by many of these tax authorities. The tax years open to examination include the years 2012 and
forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are
differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax
authorities involving issues of the timing and amount of deductions and allocations of income among various tax
jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.
We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any
currently pending uncertain tax positions will have a material adverse effect on our consolidated financial
statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a
material impact on the results of operations for that period.
77
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
Unrecognized tax benefits – January 1
Additions to tax positions related to prior years
Reductions to tax positions related to prior years
Additions to tax positions related to the current year
Settlements
Lapse of statute of limitations
Foreign currency adjustments
Unrecognized tax benefits – December 31
2022
2021
2020
$
61.9 $
55.8 $
18.1
(0.2)
9.8
(2.2)
(0.8)
(1.1)
3.2
(2.1)
18.1
(2.4)
(10.8)
0.1
$
85.5 $
61.9 $
39.2
14.0
(1.5)
3.4
—
(0.6)
1.3
55.8
Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.
Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of
December 31, 2022, 2021 and 2020 was $6.7 million, $11.8 million and $14.3 million, respectively. Bio-Rad
accrued interest and penalties of $(1.1) million, $(2.5) million, and $2.8 million for the years ended December 31,
2022, 2021, and 2020, respectively. Accrued interest as of December 31, 2022 was also reduced by $3.5 million
related to the settlement of a foreign audit. The total unrecognized tax benefits and interest and penalties of $92.2
million as of December 31, 2022 was partially offset by deferred tax assets of $17.3 million and prepaid taxes of
$7.8 million, for a net amount of $67.1 million.
As of December 31, 2022, based on the expected outcome of certain examinations or as a result of the expiration of
statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible
that our previously unrecognized tax benefits could decrease by approximately $22.2 million. Substantially all such
amounts will impact our effective income tax rate if recognized.
It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not
restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the
amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not
practicable to estimate.
8.
STOCKHOLDERS' EQUITY
Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock
(Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-
Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited
voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas
each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of
the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A
shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B
shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time
into Class A shares on a one-for-one basis at the option of the stockholder. The founders of Bio-Rad, the Schwartz
family, collectively hold a majority of Bio-Rad’s voting stock. As a result, the Schwartz family is able to exercise
control over Bio-Rad.
78
Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
Balance at January 1, 2020
Class B to Class A conversions
Issuance of common stock
Balance at December 31, 2020
Class B to Class A conversions
Issuance of common stock
Balance at December 31, 2021
Class B to Class A conversions
Issuance of common stock
Balance at December 31, 2022
Treasury Shares
Class A Shares
Class B Shares
24,966
32
75
25,073
16
45
25,134
20
8
25,162
5,090
(32)
18
5,076
(16)
18
5,078
(20)
16
5,074
The share repurchase activity under the Share Repurchase Program through open market transactions for the years
ended December 31, 2022, 2021 and 2020 are summarized as follows:
March 1, 2020 - March 31, 2020
March 1, 2021 - March 31, 2021
May 1, 2022 - May 31, 2022
November 1, 2022 - November 30, 2022
Number of
Shares
Purchased
Weighted-
Average Price
per Share
Total Shares
Repurchased
To Date
Remaining
Authorized
Value
(in millions)
291,941 $
89,506 $
255,284 $
241,408 $
342.55
558.60
489.65
375.63
573,577 $
663,083 $
918,367 $
1,159,775 $
73.1
223.1
98.1
207.4
For the years ended December 31, 2022 and 2021, we used 135,744 and 114,711, respectively, of the repurchased
shares in connection with the vesting of restricted stock units and our Employee Stock Purchase Program. As of
December 31, 2022, $207.4 million remained available for repurchases under the Share Repurchase Program.
79
9.
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Accumulated other comprehensive income (loss) included in our consolidated balance sheets and consolidated
statements of changes in stockholders' equity consists of the following components (in millions):
Foreign currency
translation
adjustments
Foreign other
post-employment
benefits
adjustments
Net unrealized
holding gains
(losses) on
available-for-sale
investments
Total
Accumulated
other
comprehensive
income (loss)
Balances as of January 1, 2021
$
298.6 $
(26.0) $
9.8 $
282.4
Other comprehensive (loss) income,
before reclassifications
Amounts reclassified from accumulated
other comprehensive income
Income tax effects
Other comprehensive income (loss), net of
income taxes
Balances as of December 31, 2021
Other comprehensive income (loss),
before reclassifications
Amounts reclassified from accumulated
other comprehensive income
Income tax effects
Other comprehensive income (loss), net of
income taxes
$
Balances as of December 31, 2022
$
(469.5)
—
0.4
(469.1)
(170.5) $
(296.3)
—
0.3
(296.0)
(466.5) $
17.9
0.3
(3.1)
15.1
(10.9) $
25.4
0.1
(4.6)
20.9
10.0 $
(4.0)
(1.2)
1.2
(4.0)
5.8 $
(21.5)
0.6
4.8
(16.1)
(10.3) $
(455.6)
(0.9)
(1.5)
(458.0)
(175.6)
(292.4)
0.7
0.5
(291.2)
(466.8)
All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into Other
(income), net in the consolidated statements of income. Reclassification adjustments are calculated using the
specific identification method.
10.
SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS
Equity Award Plan
The 2017 Incentive Award Plan (2017 Plan) authorizes the grant of stock options, restricted stock, restricted stock
units, performance-based stock units and other types of equity awards to officers and certain other employees. Stock
options are granted at exercise prices not less than the fair market value of the underlying common stock on the date
of grant and have a maximum term of 10 years. We may issue stock options for either Class A or Class B common
stock. Prior to September 2020, equity awards granted vest in increments of 20% per year on the yearly anniversary
date of the grant. Starting in September 2020, equity awards granted vest in increments of 25% per year on the
yearly anniversary date of the grant.
A total of 2,108,724 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of
either Class A or Class B common stock. At December 31, 2022, there were 1,259,719 shares available to be
granted.
80
Performance-based Stock awards
Bio-Rad grants certain executive officers Performance-based stock unit (PSU) awards, which are administered
under the 2017 Plan. PSUs generally vest over a three year performance period based on achievement of specific
performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200
percent of the target award.
We consider the dilutive impact of PSUs in our diluted net income per share calculation only to the extent that the
performance conditions would have been met if the reporting period was the end of the performance period.
Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to the
greater of 10% of their compensation or $25,000 annually towards the quarterly purchase of our Class A common
stock. The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business
day or the last business day of each calendar quarter. The Board of Directors have authorized the sale of 1,300,000
shares of Class A common stock under the 2011 ESPP.
Share-Based Compensation
Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases
and restricted stock unit awards, including performance-based stock awards. Share-based compensation expense is
allocated in the consolidated statements of income (loss) as follows (in millions):
Cost of goods sold
Selling, general and administrative expense
Research and development expense
Share-based compensation expense
Year ended December 31,
2021
2020
2022
$
$
5.4
45.6
9.9
60.9
$
$
4.9
38.0
8.3
51.2
$
$
3.4
31.8
6.4
41.6
The income tax benefit related to share-based compensation expense was $8.8 million, $7.4 million and $6.0 million
for the years ended December 31, 2022, 2021 and 2020, respectively. We did not capitalize any share-based
compensation expense as it was immaterial.
The tax benefit from equity awards vested or exercised during the years ended December 31, 2022, 2021 and 2020
was $4.0 million, $18.5 million and $11.2 million, respectively.
For equity awards, we amortize the fair value on a straight-line basis. All equity awards are amortized over the
requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they
occur.
81
Stock Options
The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model
with the following weighted-average assumptions:
Year Ended December 31,
2021
2020
2022
Expected volatility
Risk-free interest rate
Expected life (in years)
Expected dividend
Weighted-average fair value of options granted
$
—
—
0.0
—
— $
27 %
1.05 %
7.3
27 %
0.31 %
7.4
—
251.93
$
—
153.32
Expected volatility is based on the historical volatilities of our common stock for a period equal to the stock
option’s expected life. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the
grant. The expected life represents the number of years that we estimate, based primarily on historical experience,
that the options will be outstanding prior to exercise. We do not anticipate paying any cash dividends in the future
and therefore use an expected dividend yield of zero.
The following table summarizes stock option activity:
Outstanding, December 31, 2021
Granted
Exercised
Forfeited
Outstanding, December 31, 2022
Unvested, December 31, 2022
Exercisable, December 31, 2022
Weighted-
Average
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term (in
years)
Aggregate
Intrinsic
Value
(in millions)
246.41
—
107.32
368.81
270.03
539.67
210.77
4.10 $
7.47 $
3.36 $
39.5
1.4
38.1
Shares
250,441 $
— $
(39,250) $
(4,771) $
206,420 $
37,192 $
169,228 $
Intrinsic value for stock options is defined as the difference between the current market value and the exercise price.
The total intrinsic value on the date of exercise of stock options exercised during the years ended December 31,
2022, 2021 and 2020 was $15.2 million, $33.0 million and $24.4 million, respectively.
No cash was received from stock options exercised during the year ended December 31, 2022. Cash received from
stock options exercised during the years ended December 31, 2021 and 2020 was $3.6 million and $3.8 million,
respectively.
As of December 31, 2022, there was $5.2 million of total unrecognized compensation expense from stock options.
This amount is expected to be recognized in the future over a remaining weighted-average period of approximately
two years.
82
Restricted Stock Units - Service & Performance-based
Restricted stock units are rights to receive shares of company stock. The fair value of a restricted stock unit is the
market value as determined by the closing price of the stock on the day of grant.
The following tables summarize restricted stock units and performance-based stock units activity:
Restricted Stock
Units
Weighted-
Average
Grant-Date
Fair Value
Weighted-
Average
Remaining
Contractual Term
(in years)
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31,
2021
Granted
Vested
Forfeited
Outstanding, December 31,
2022
316,860
140,560
(113,323)
(29,855)
314,242
$
$
$
$
$
495.57
486.29
433.46
463.70
516.85
1.67 $
132.1
Performance-
based Stock
Units
Weighted-
Average
Grant-Date
Fair Value
Weighted-
Average
Remaining
Contractual Term
(in years)
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31,
2021
Granted
Vested
Forfeited
Outstanding, December 31,
2022
— $
$
— $
— $
$
11,391
11,391
—
486.25
—
—
486.25
1.83 $
4.8
The total fair value of restricted stock units and performance-based stock units vested for the years ended
December 31, 2022, 2021 and 2020 was $54.5 million, $104.4 million and $65.0 million, respectively. As of
December 31, 2022, there was approximately $142.6 million and $9.4 million of total unrecognized compensation
expense related to restricted stock units and performance-based stock units, respectively. This amount is expected to
be recognized over a remaining weighted-average period of approximately three years.
Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model
with the following weighted-average assumptions:
Expected volatility
Risk-free interest rate
Expected life (in years)
Expected dividend
Weighted-average fair value
of purchase rights
Year Ended December 31,
2021
2020
2022
41 %
1.71 %
0.25
—
25 %
0.05 %
0.25
—
41 %
0.50 %
0.25
—
$
124.26
$
127.16
$
94.93
83
The assumptions are primarily based on historical data. Volatility is based on the historical volatilities of our
common stock for a period equal to the expected life of the purchase rights. The risk-free interest rate is based on
the U.S. Treasury yield curve in effect at the time of the grant. We do not anticipate paying any cash dividends in
the future and therefore use an expected dividend yield of zero.
We sold 44,480 shares for total employee contributions of $17.6 million, 31,639 shares for total employee
contributions of $17.0 million and 47,548 shares for total employee contributions of $16.4 million under the 2011
ESPP to employees for the years ended December 31, 2022, 2021 and 2020, respectively. At December 31, 2022,
475,864 shares remain authorized and available for issuance under the 2011 ESPP.
11.
OTHER (INCOME), NET
Other (income) expense, net includes the following components (in millions):
Year Ended December 31,
2021
2022
2020
Interest and investment income
Net realized gains on investments
Other-than-temporary impairment losses on investments
Current expected credit losses on loans to equity method investees
Gain on divestiture of a division
Other (income) expense
Other (income), net
$
$
(58.0) $
(2.3)
11.9
7.5
(1.4)
(2.3)
(44.6) $
(18.9) $
(8.0)
0.8
—
—
(0.7)
(26.8) $
(18.2)
(1.0)
4.6
—
(11.7)
1.8
(24.5)
84
12.
SUPPLEMENTAL CASH FLOW INFORMATION
The following supplemental cash flow information at December 31, 2021 and 2020 has been revised to correct for
immaterial errors in prior periods as described in Note 1, “Immaterial Correction to Previously Issued Financial
Statements.”
The reconciliation of net income (loss) to net cash provided by operating activities is as follows (in millions):
Year Ended December 31,
2021
2020
2022
(3,627.5) $
4,254.3 $
3,814.2
137.3
39.9
60.9
11.9
7.5
5,193.6
(1.4)
(38.1)
(87.4)
(158.8)
(27.3)
137.6
39.3
51.2
0.8
—
(4,926.2)
—
(40.7)
(20.4)
46.1
(12.9)
(94.2)
(1.2)
(1,241.6)
(5.1)
5.6
20.3
194.4 $
69.9
(28.8)
1,084.9
(6.2)
10.5
10.1
669.5 $
7.3 $
— $
— $
5.2 $
6.0 $
— $
138.6
37.1
41.6
4.6
—
(4,495.8)
(11.7)
(36.5)
(15.0)
(52.1)
(9.1)
124.7
39.0
981.4
(6.9)
26.9
4.0
585.0
1.2
4.6
—
Net income (loss)
Adjustments to reconcile net income (loss)
to net cash provided by operating activities
Depreciation and amortization
Reduction in the carrying amount of right-of-use assets
Share-based compensation
Other-than-temporary impairment losses on investments
Current expected credit losses on loans
(Gains) losses from change in fair market value of equity
securities and loan receivable
Gain on divestiture of a division
Payments for operating lease liabilities
Increase in accounts receivable
(Increase) decrease in inventories
Increase in other current assets
Increase (decrease) in accounts payable and other current
liabilities
Increase (decrease) in income taxes payable
Increase (decrease) in deferred income taxes
Increase in other long-term assets
Increase in other long-term liabilities
Other
Net cash provided by operating activities
Non-cash investing activities:
Purchased property, plant and equipment
Purchased marketable securities and investments
Sold marketable securities and investments
$
$
$
$
$
85
13.
COMMITMENTS AND CONTINGENT LIABILITIES
Deferred Profit Sharing Retirement Plan
We have a profit sharing plan covering substantially all U.S. employees. Contributions are made at the discretion of
management. As of December 31, 2022 and 2021, the liability related to the U.S. profit sharing plan was
$1.2 million and $3.8 million, respectively. The contribution expense was $19.1 million, $18.4 million and $10.6
million for the years ended December 31, 2022, 2021 and 2020, respectively.
Purchase Obligations
As of December 31, 2022, we had purchase obligations that have not been recognized on our balance sheet of
$17.2 million, which include agreements to purchase goods or services that are enforceable and legally binding to
Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.
Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad.
The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our
balance sheet as of December 31, 2022 were as follows in millions:
2023
2024
2025
2026
2027
2028 and thereafter
Long-Term Liabilities
$
17.1
0.1
—
—
—
—
As of December 31, 2022, we had obligations that have been recognized on our balance sheet of $123.0 million,
which primarily represent long-term deferred revenue and other post-employment benefits. Excluded are tax
liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future
cash flows of these tax liabilities, therefore, our income tax obligations are excluded.
The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet
as of December 31, 2022 were as follows in millions:
2023
2024
2025
2026
2027
2028 and thereafter
Letters of Credit/Guarantees
$
4.6
13.8
21.6
4.1
43.7
35.2
In the ordinary course of business, we are at times required to post letters of credit/guarantees. The letters of credit/
guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently
liable for $4.7 million of standby letters of credit/guarantees with financial institutions as of December 31, 2022.
86
Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination
indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined
benefit plans and the associated net benefit obligation as of December 31, 2022 and 2021 of $46.8 million and
$76.1 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term
liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust
or other device used to accumulate assets or settle these obligations. However, some of these plans require funding
based on local laws in which there is a trust or other device administered by an external plan manager that is used to
accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are
located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.
Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in
the Consolidated Balance Sheets for the plans (in millions):
Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Plan participants' contributions
Actuarial (gain) loss
Gross benefits paid
Plan amendments
Curtailments
Settlements
Foreign currency adjustments
Benefit obligation at end of year
Change in plan assets:
Fair value of plan assets at beginning year
Actual return on plan assets
Employer contributions
Plan participants' contributions
Gross benefits paid
Settlements
Foreign currency adjustments
Fair value of plan assets at end of year
2022
2021
$155.5
6.6
0.8
3.1
(23.5)
0.7
(1.0)
—
(7.6)
(5.4)
129.2
79.4
1.5
4.3
3.1
2.8
(7.6)
(1.1)
82.4
$177.5
8.0
0.5
3.2
(10.2)
(0.7)
(1.7)
(3.3)
(9.5)
(8.3)
155.5
81.4
1.3
4.3
3.2
1.3
(9.5)
(2.6)
79.4
Underfunded status of plans
$(46.8)
$(76.1)
Amounts recognized in the consolidated balance
sheets:
Current liabilities (Accrued payroll and employee
benefits)
Noncurrent liabilities (Other long-term liabilities)
Net liability, end of fiscal year
$(1.5)
(45.3)
$(46.8)
$(2.3)
(73.8)
$(76.1)
87
Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):
2022
2021
2020
Service costs
Interest costs
Expected returns on plan assets
Amortization of actuarial losses
Amortization of prior service costs
Curtailments
Settlements
Net periodic benefit costs
Assumptions
$6.6
0.8
(1.0)
0.3
(0.3)
—
(0.2)
$6.2
$8.0
0.5
(1.0)
1.8
—
(1.9)
1.2
$8.6
The above actuarial net gains were primarily based on financial, demographic and experience assumptions.
The weighted-average assumptions used in computing the benefit obligations were as follows:
Discount rate
Compensation rate increase
2022
2021
2.6 %
1.7 %
The weighted-average assumptions used in computing the net periodic benefit costs were as follows:
2022
2021
2020
Discount rate
Expected long-term rate of return on plan assets
0.6 %
1.3 %
0.3 %
1.1 %
$7.8
0.8
(0.7)
1.3
—
—
1.3
$10.5
0.6 %
1.5 %
0.5 %
1.5 %
The accumulated benefit obligation (ABO), an estimate based on the assumption if these plans were to be
terminated immediately, as of December 31, 2022 and 2021 was $114.9 million and $142.1 million, respectively.
The ABO and fair value of plan assets for these plans with ABO in excess of plan assets were $32.5 million and
$62.7 million as of December 31, 2022 and 2021, respectively.
In some foreign locations we have service award plans that are paid based upon the number of years of employment.
Under these plans, the liability as of December 31, 2022 and 2021 was $2.5 million and $3.5 million, respectively,
and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated
Balance Sheets.
Concentrations of Labor Subject to Collective Bargaining Agreements
At December 31, 2022, approximately seven percent of Bio-Rad's approximately 3,450 U.S. employees were
covered by a collective bargaining agreement, which will expire on November 14, 2023. Many of Bio-Rad's non-
U.S. full-time employees, especially in France, are covered by collective bargaining agreements.
88
14.
LEGAL PROCEEDINGS
We are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we
do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material
adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding
the ultimate outcome of these matters and their resolution could be material to our operating results for any
particular period, depending on the level of income for the period.
15.
SEGMENT INFORMATION
Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and
clinical diagnostics products. We have two reportable segments: Life Science and Clinical Diagnostics. These
reportable segments are strategic business lines that offer more than 12,000 different products and services and
require different marketing strategies. We do not disclose quantitative information about our different products and
services as it is impractical to do so based primarily on the numerous products and services that we sell and the
global markets that we serve.
The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for
biological research. These products are sold to university and medical school laboratories, pharmaceutical and
biotechnology companies, food testing laboratories and government and industrial research facilities.
The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics
systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference
laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories and transfusion
laboratories.
Other Operations include our Analytical Instruments segment, and a small miscellaneous operation that was
included in a prior acquisition.
Segment results are presented in the same manner as we present our operations internally to make operating
decisions and assess performance. The accounting policies of the segments are the same as those described in
Significant Accounting Policies (see Note 1). Our chief operating decision maker ("CODM") views all operating
expenses including depreciation and amortization and corporate overhead as directly supporting the strategies of our
segments and these costs are fully allocated to our reportable segments. The CODM evaluates the performance of
our segments and allocates resources primarily based on operating income, which represents revenues reduced by
product costs and operating expenses. Starting in 2022, segment assets include net inventories as this is the only
asset considered to be under the control of the segment and the only asset for which segment information is
provided to the CODM. The historical segment information has been recast to conform to the current methodology.
The following segments information regarding industry segments at December 31, 2021 and 2020 have been
revised to correct for immaterial errors in prior periods as described in Note 1, “Immaterial Correction to Previously
Issued Financial Statements.”
89
Information regarding industry segments at December 31, 2022, 2021, and 2020 and for the years then ended is as
follows (in millions):
Net sales
Depreciation and amortization
Operating profit (loss)
Segment assets
Life
Science
$ 1,347.2
1,400.8
1,231.8
Clinical
Diagnostics
1,451.0
$
1,515.9
1,305.2
Other
Operations
4.0
$
5.8
8.6
$
$
$
$
$
$
57.9
54.8
50.5
266.8
319.7
282.6
269.9
207.7
220.6
$
$
$
79.4
82.8
88.1
217.7
181.8
138.3
448.8
363.5
401.2
—
—
—
(1.9)
(1.2)
0.4
0.6
1.0
0.5
2022
2021
2020
2022
2021
2020
2022
2021
2020
2022
2021
2020
The following reconciles total operating profit to consolidated income before taxes (in millions):
Year Ended December 31,
2021
2020
2022
Total operating profit
Interest expense
Foreign currency exchange gains (losses), net
Gains (losses) from change in fair market value of equity securities and loan
receivable
Other income, net
Consolidated income (loss) before income taxes
$
482.6 $
(38.1)
0.2
(5,193.6)
500.3 $
(1.5)
(2.7)
4,926.2
421.3
(21.9)
(1.7)
4,495.8
44.6
26.8
24.5
$ (4,704.3) $ 5,449.1 $ 4,918.0
The following reconciles total segment assets to consolidated total assets (in millions):
December 31,
2022
2021
Total segment assets
Cash, short-term investments and other current assets
Property, plant and equipment, net, and operating lease right-of-use assets
Goodwill, net
Other long-term assets
Total assets
90
$
719.3 $
572.2
1,418.3
716.4
347.3
14,745.2
$ 13,501.7 $ 17,799.4
2,438.7
679.6
406.5
9,257.6
The following presents net sales to external customers by geographic region based primarily on the location of the
use of the product or service (in millions):
United States
Europe
Asia
Other (primarily Canada and Latin America)
Total net sales
Year Ended December 31,
2021
2022
2020
1,155.5 $
851.9
639.4
155.4
2,802.2 $
1,130.6 $
946.9
688.4
156.6
2,922.5 $
1,004.8
857.7
546.5
136.6
2,545.6
$
$
The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets,
excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):
United States
Europe
Asia
Other (primarily Canada and Latin America)
Total Property, plant and equipment, net, Operating lease right-of-use assets
and Other assets, excluding deferred income taxes
$
$
December 31,
2022
2021
465.7 $
183.7
63.8
15.6
728.8 $
478.7
211.4
64.9
16.5
771.5
16.
RESTRUCTURING COSTS
In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to
improve operating performance. The restructuring plan primarily impacts our operations in EMEA and includes the
elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing
operations from EMEA to APAC. The restructuring plan is being implemented in phases and is expected to be
substantially complete by mid-2023. The liability of $31.6 million as of December 31, 2022 consisted of $31.5
million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Account payable in the
consolidated balance sheets. The expense and adjustments to expense recorded were reflected in Cost of goods sold
of $1.1 million and $25.0 million, in Selling, general and administrative expense of $3.0 million and $26.1 million
and in Research and development expense of $0.1 million and $13.3 million in the consolidated statements of
income (loss) for the years ended December 31, 2022 and December 31, 2021, respectively. The adjustments to
expense recorded were primarily due to extension of termination dates for certain employees, changes in the
estimates of employee termination benefits and employees resigning or transferring to different positions within the
company. From February 2021 to December 31, 2022, total expenses were $68.6 million.
91
The following table summarizes the activity of our European reorganization restructuring reserves (in millions):
Balances as of January 1
$
5.2 $
41.9 $
47.1 $
— $
— $ —
Life
Science
2022
Clinical
Diagnostics
Total
Life
Science
2021
Clinical
Diagnostics
Total
Charged to expense - employee
termination benefits
Adjustment to expense
Cash payments
Foreign currency adjustments
Balances as of December 31
17.
LEASES
—
1.1
(4.1)
(0.3)
1.9 $
—
3.1
(12.7)
(2.6)
29.7 $
—
4.2
(16.8)
(2.9)
31.6 $
12.9
(3.3)
(4.0)
(0.4)
5.2 $
62.7
(7.9)
(10.2)
(2.7)
41.9 $
75.6
(11.2)
(14.2)
(3.1)
47.1
$
We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases
have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options.
The components of lease expense were as follows (in millions):
Operating lease cost
Finance lease cost:
Amortization of right-to-use assets
Interest on lease liabilities
Total finance lease cost
Sublease income
Year Ended December 31,
2021
2020
2022
57.5 $
53.2 $
45.4
0.4 $
0.8
1.2 $
3.0 $
0.5 $
0.8
1.3 $
3.0 $
0.6
0.8
1.4
3.0
$
$
$
$
The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of
remeasurements, modifications, impairments and abandonments.
Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not
significant for the years ended December 31, 2022, 2021 and 2020. Operating lease variable cost is primarily
comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for
the years ended December 31, 2022, 2021 and 2020.
92
Supplemental cash flow information related to leases were as follows (in millions):
Year Ended December 31,
2021
2020
2022
Cash paid for amounts included in the measurement of lease
liabilities:
Operating cash flows from operating leases
Operating cash flows from finance leases
Financing cash flows from finance leases
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
Finance leases
$
$
$
$
$
38.1 $
0.8 $
0.4 $
21.2 $
0.1 $
40.7 $
0.5 $
0.8 $
45.5 $
— $
Supplemental balance sheet information related to leases were as follows (in millions):
Operating Leases
Operating lease right-of-use assets
Current operating lease liabilities
Operating lease liabilities
Total operating lease liabilities
December 31,
2022
2021
$
$
$
181.0 $
36.3 $
153.6
189.9 $
44.4
0.6
0.8
16.1
0.4
204.8
36.4
175.9
212.3
Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term
debt and notes payable, net of current maturities.
December 31,
2022
2021
Finance Leases
Property, plant and equipment, gross
Less: accumulated depreciation and amortization
Property, plant and equipment, net
Current maturities of long-term debt and notes payable
Long-term debt, net of current maturities
Total finance lease liabilities
$
$
$
$
11.9 $
(5.5)
6.4 $
0.5 $
10.1
10.6 $
Weighted Average Remaining Lease Term
Operating leases - in years
Finance leases - in years
Weighted Average Discount Rate
Operating leases
Finance leases
93
December 31,
2022
2021
7
15
3.0 %
6.3 %
11.8
(5.1)
6.7
0.5
10.5
11.0
8
15.5
3.3 %
6.3 %
Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,
2023
2024
2025
2026
2027
Thereafter
Total lease payments
Less imputed interest
Total
Operating
Leases
Finance
Leases
43.6
36.3
32.5
25.8
20.7
57.5
216.4
(26.5)
189.9
$
$
1.2
1.2
1.1
1.1
1.0
11.9
17.5
(6.9)
10.6
$
$
The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value
vehicles and other equipment with shorter terms and higher-turn over.
As of December 31, 2022, operating leases that have not commenced are not material.
18.
QUARTERLY FINANCIAL DATA (UNAUDITED)
The following tables provide unaudited condensed consolidated quarterly financial data for all of the periods in the
years ended December 31, 2022 and 2021, which have been revised to correct for an immaterial error in prior
periods as detailed below and further described in Note 1 “Immaterial Correction to Previously Issued Financial
Statements.”
Summarized quarterly financial data for the years ended December 31, 2022 and 2021 are as follows (in millions,
except per share data):
2022
Net sales
Gross profit
Net income (loss)
Basic earnings (loss) per share
Diluted earnings (loss) per share
2021
Net sales
Gross profit
Net income
Basic earnings per share
Diluted earnings per share
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
$
$
700.1 $
402.6
(3,367.3)
(112.5)
(112.5)
726.8 $
400.5
980.0
32.86
32.46
691.1 $
395.0
(925.1)
(31.05)
(31.05)
715.9 $
401.1
916.8
30.80
30.41
680.8 $
372.6
(162.8)
(5.48)
(5.48)
730.3
397.1
827.7
27.89
27.78
747.0 $
436.5
3,929.6
131.80
130.02
732.8
399.9
(1,572.2)
(52.54)
(52.54)
94
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
ITEM 9A. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information
required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed,
summarized, and reported within the time periods specified in Securities and Exchange Commission rules and
forms, and that such information is accumulated and communicated to our management, including our Chief
Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions
regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management
recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its
judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of
any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions.
Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated
the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year
covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO concluded that our
disclosure controls and procedures were effective to meet the objective for which they were designed and operate at
the reasonable assurance level.
(b) Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting
for the Company as defined in Rule 13a-15(f) or 15(d)-15(f) of the Exchange Act. Our internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S.
generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
Company’s assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles,
and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use or disposition of our assets that could have a material effect on our consolidated financial
statements.
Our management assessed the effectiveness of the Company’s internal control over financial reporting as of
December 31, 2022 using the criteria established in Internal Control - Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment and
those criteria, management concluded that our internal control over financial reporting was effective as of
December 31, 2022. Our internal control over financial reporting has been audited by KPMG, LLP, an independent
registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Form 10-K.
95
(c) Changes in Internal Control over Financial Reporting
Management continuously reviews disclosure controls and procedures, and internal control over financial reporting,
and accordingly may, from time to time, make changes aimed at enhancing their effectiveness to ensure that its
systems evolve with its business. There were no changes in our internal controls over financial reporting (as
defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the year ended December 31, 2022 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(d) Inherent Limitations on Effectiveness of Internal Controls
Because of its inherent limitations, our internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.
ITEM 9B. OTHER INFORMATION
Not applicable.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
PART III.
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of
Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2023 annual meeting of
stockholders (the “2023 Proxy Statement”) under “Executive Officers,” “Election of Directors,” “Committees of the
Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.”
Bio-Rad’s Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda
Litherland is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K. Each of Jeffrey
L. Edwards, Gregory K. Hinckley and Melinda Litherland is also an “independent” director, as determined in
accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as
amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual.
We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal
financial officer, controller (or persons performing similar functions), all other employees and our directors. It is
available through the Corporate Governance section of our website (www.bio-rad.com). We will also provide a
copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories,
Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA 94547.” We intend to satisfy any disclosure
requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of
ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com) within
four business days following the date of the amendment or waiver.
96
ITEM 11. EXECUTIVE COMPENSATION
The information required to be furnished pursuant to this item is incorporated by reference from portions of the
2023 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants
of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested
Table,” “Pension Benefits,” “Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or
Change in Control,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and
"Pay Ratio Disclosure.” In addition, the information from a portion of the 2023 Proxy Statement under
“Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall
not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of
the 2023 Proxy Statement under “Principal and Management Stockholders.”
Equity Compensation Plan Information as of December 31, 2022
Plan category
Equity compensation
plans approved by
security holders (1)
Equity compensation
plans not approved by
security holders
Total
Number of securities
to be issued
upon exercise of
outstanding options,
warrants and rights
(a)
Weighted-average exercise
price of
outstanding options,
warrants and rights
(b)(3)
Number of securities remaining
available for future issuance under
equity compensation plans (excluding
securities reflected in column (a))
(c)
532,053
$
—
532,053
$
270.03
—
270.03
1,735,583
(2)
—
1,735,583
(1) Consists of the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan, the Bio-Rad Laboratories, Inc. 2017 Incentive
Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(2) Consists of 1,259,719 shares available under the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan and 475,864
shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(3) Excludes Restricted Stock Units and Performance Stock Units.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The information required to be furnished pursuant to this item is incorporated by reference from portions of the
2023 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.”
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Our independent registered public accounting firm is "KPMG LLP, Santa Clara, CA, Auditor Firm ID: 185"
The information required to be furnished by this item is incorporated by reference from a portion of the 2023 Proxy
Statement under “Report of the Audit Committee of the Board of Directors.”
97
PART IV.
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)1
Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and
Supplementary Data" on page 42 for a list of financial statements.
2
Schedule II Valuation and Qualifying Accounts
All financial statement schedules are omitted because they are not required, or the required
information is included in the consolidated financial statements or the notes thereto.
3.
Index to Exhibits
The exhibits listed below in the accompanying Index to Exhibits are filed or incorporated by reference as part
of this report.
BIO-RAD LABORATORIES, INC.
INDEX TO EXHIBITS ITEM 15(a)3
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of
1934.”
Exhibit No.
3.1 Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1)
3.1.1 Certificate of Amendment to Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1)
3.2 Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. (2)
4.1 Description of Bio-Rad Laboratories, Inc. Class A and Class B Common Stock (3)
4.2 Indenture, dated as of March 2, 2022, by and between Bio-Rad Laboratories, Inc. and Wilmington Trust, National
Association. (4)
4.3 First Supplemental Indenture, dated as of March 2, 2022, by and between Bio-Rad Laboratories, Inc. and
Wilmington Trust, National Association. (5)
4.4 Form of Global Security for the 3.300% Senior Notes due 2027. (6)
4.5 Form of Global Security for the 3.700% Senior Notes due 2032. (7)
10.1 Credit Agreement, dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to
therein, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA
National Association, and Mug Bank, Ltd., as co-syndication agents, and Citibank, N.A., and Wells Fargo Bank,
N.A., National Association as co-documentation agents. (8)
98
10.1.1 Amendment No. 1 dated as of November 15, 2021 to Credit Agreement dated as of April 15, 2019, by and among
Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as
administrative agent. (9)
10.1.2 Amendment No. 2 dated as of April 15, 2022 to Credit Agreement dated as of April 15, 2019, by and among Bio-
Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as
administrative agent. (10)
10.1.3 Amendment No. 3 dated as of February 1, 2023 to Credit Agreement dated as of April 15, 2019, by and among
Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as
administrative agent.
10.2 Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan. (11)*
10.2.1 First Amendment to the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan (12)*
10.3 Employees’ Deferred Profit Sharing Retirement Plan (Amended and Restated effective January 1, 1997). (13)*
10.4 2007 Incentive Award Plan. (14)*
10.4.1 Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2007
Incentive Award Plan. (15)*
10.4.2 Amendment to the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan. (16)*
10.5 Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (17)*
10.5.1 Global Restricted Stock Unit Award Grant Notice and Global Restricted Stock Unit Award Agreement under
2017 Incentive Award Plan (18)*
10.5.2 Stock Option Grant Notice and Non-Qualified Stock Option Agreement under 2017 Incentive Award Plan (19)*
10.5.3 Global Restricted Stock Unit Award Grant Notice and Global Restricted Stock Unit Award Agreement under
2017 Incentive Award Plan (updated September 2020) (20)*
10.5.4 Stock Option Grant Notice and Non-Qualified Stock Option Agreement under 2017 Incentive Award Plan
(updated September 2020) (21)*
10.5.5 Performance Stock Unit Award Agreement under 2017 Incentive Award Plan. (22)*
10.6 Employment Offer Letter between the Company and Ilan Daskal dated March 15, 2019 (23)*
10.7 Employment Offer Letter between the Company and Andrew J. Last dated March 15, 2019 (24)*
10.8 Form of Indemnification Agreement. (25)
10.9 Executive Change in Control Severance Plan (26)*
21.1 Listing of Subsidiaries
23.1 Consent of Independent Registered Public Accounting Firm
99
31.1 Certification of Chief Executive Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a))
31.2 Certification of Chief Financial Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a))
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within
the inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101
(1) Incorporated by reference to Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended
December 31, 2010.
(2) Incorporated by reference to Exhibit 3.1 to Bio-Rad’s Form 8-K filing, dated October 27, 2017.
(3) Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 10-K filing, dated March 2, 2020.
(4) Incorporated by reference to Exhibit 4.1 to Bio-Rad’s 8-K filing, dated March 2, 2022
(5) Incorporated by reference to Exhibit 4.2 to Bio-Rad’s 8-K filing, dated March 2, 2022.
(6) Incorporated by reference to Exhibit 4.3 to Bio-Rad’s 8-K filing, dated March 2, 2022.
(7) Incorporated by reference to Exhibit 4.4 to Bio-Rad’s 8-K filing, dated March 2, 2022.
(8) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 16, 2019.
(9) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated November 18, 2021.
(10) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 20, 2022.
(11) Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011.
(12) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017.
(13) Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated
November 13, 1997.
(14) Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007.
100
(15) Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated
November 4, 2009.
(16) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014.
(17) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017.
(18) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017.
(19) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017.
(20) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated October 30, 2020.
(21) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated October 30, 2020.
(22) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 10-Q filing, dated October 28, 2022.
(23) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 2, 2019.
(24) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 22, 2019.
(25) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated August 7, 2017.
(26) Incorporated by reference to Exhibit 10.9 to Bio-Rad’s Form 10-K filing, dated February 11, 2022.
* Indicates a management contract or compensatory plan or arrangement.
Item 16. FORM 10-K SUMMARY
None.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
BIO-RAD LABORATORIES, INC.
By:
/s/ Ilan Daskal
(Ilan Daskal)
Executive Vice President, Chief Financial Officer
Date:
February 17, 2023
101
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Principal Executive Officer:
/s/ Norman Schwartz
(Norman Schwartz)
Principal Financial Officer:
/s/ Ilan Daskal
(Ilan Daskal)
Principal Accounting Officer:
/s/ Ajit Ramalingam
(Ajit Ramalingam)
Other Directors:
/s/ Jeffrey L. Edwards
(Jeffrey L. Edwards)
Chairman of the Board, President
and Chief Executive Officer
February 17, 2023
Executive Vice President,
Chief Financial Officer
February 17, 2023
Senior Vice President,
Chief Accounting Officer
February 17, 2023
Director
February 17, 2023
/s/ Gregory K. Hinckley
Director
February 17, 2023
(Gregory K. Hinckley)
/s/ Melinda Litherland
(Melinda Litherland)
/s/ Arnold A. Pinkston
(Arnold A. Pinkston)
/s/ Allison Schwartz
(Allison Schwartz)
Director
Director
Director
February 17, 2023
February 17, 2023
February 17, 2023
102
[THIS PAGE INTENTIONALLY LEFT BLANK]
[THIS PAGE INTENTIONALLY LEFT BLANK]
BIO-RAD LABORATORIES CORPORATE INFORMATION
ANNUAL MEETINGThe Annual Meeting of Stockholders will be held at Bio-Rad’s corporate offices, 1000 Alfred Nobel Drive, Hercules, California 94547, on Tuesday, April 25, 2023, at 4:00 PM Pacific Time.Bio-Rad will provide without charge to each stockholder, upon written request to the Secretary, a copy of its 2022 Annual Report filed with the Securities and Exchange Commission on Form 10-K.TRANSFER AGENTComputersharec/o Shareholder Services 462 South 4th Street, Suite 1600 Louisville, KY 40202 www.computershare.comAUDITORSKPMG LLPCOMMON STOCKTraded on the New York Stock Exchange Class A Common Stock Symbol BIOClass B Common Stock Symbol BIObOTHER SENIOR EXECUTIVESJim BarrySenior Vice President, Global ManufacturingLee BoydSenior Vice President, Global Commercial Operations, Asia PacificColleen CoreyExecutive Vice President, Global Human ResourcesKurt DeLangheSenior Vice President, Global Commercial Operations, Europe, Middle East, AfricaBob DoustSenior Vice President, Research & Development, Clinical Diagnostics GroupCarla EvansSenior Vice President, Global Real Estate & FacilitiesErik MolitorChief Information Officer, Global Technology & SystemsMorgan NorrisSenior Vice President, Marketing, Life Science GroupJonathan SeatonSenior Vice President, Corporate Business DevelopmentMatthew WernerSenior Vice President, Chief Compliance & Privacy OfficerMario WijkerSenior Vice President, Regulatory Affairs & Quality AssuranceDIRECTORSNorman SchwartzChairman of the BoardJeffrey L. EdwardsDirectorGregory K. HinckleyDirectorMelinda LitherlandDirectorArnold A. PinkstonDirectorAllison SchwartzDirector Alice N. SchwartzDirector EmeritusOFFICERSNorman SchwartzPresident and Chief Executive OfficerAndrew LastExecutive Vice President, Chief Operating OfficerIlan DaskalExecutive Vice President, Chief Financial OfficerMichael CrowleyExecutive Vice President, Global Commercial OperationsTimothy S. ErnstExecutive Vice President, General Counsel & SecretaryDiane DahowskiExecutive Vice President, Global Supply ChainSimon MayExecutive Vice President, President, Life Science GroupDara WrightExecutive Vice President, President, Clinical Diagnostics GroupAjit RamalingamSenior Vice President, Chief Accounting Officer CORPORATE OFFICES
1000 Alfred Nobel Drive
Hercules, California 94547 USA
+1 510-724-7000 PHONE
+1 510-741-5817 FAX
www.bio-rad.com
i
B
o
-
R
a
d
L
a
b
o
r
a
t
o
r
i
e
s
A
n
n
u
a
l
R
e
p
o
r
t
2
0
2
2